10-Q
UNITED STATES
SECURITIES AND EXCHANGE
COMMISSION
Washington, D.C.
20549
Form 10-Q
|
|
|
þ
|
|
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
|
|
|
For the quarterly period ended
September 30, 2008
|
or
|
o
|
|
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
|
(Commission File Number)
001-32410
CELANESE CORPORATION
(Exact Name of Registrant as
Specified in its Charter)
|
|
|
Delaware
|
|
98-0420726
|
(State or Other Jurisdiction
of
Incorporation or Organization)
|
|
(I.R.S. Employer
Identification No.)
|
|
|
|
1601 West LBJ Freeway,
Dallas, TX
(Address of Principal
Executive Offices)
|
|
75234-6034
(Zip Code)
|
(Registrants telephone number, including area code)
(972) 443-4000
Indicate by check mark whether the registrant (1) has filed
all reports required to be filed by Section 13 or 15(d) of
the Securities Exchange Act of 1934 during the preceding
12 months (or for such shorter period that the registrant
was required to file such reports), and (2) has been
subject to such filing requirements for the past
90 days. Yes þ No o
Indicate by check mark whether the registrant is a large
accelerated filer, an accelerated filer, a non-accelerated
filer, or a smaller reporting company. See the definitions of
large accelerated filer, accelerated
filer and smaller reporting company in Rule
12b-2 of the
Exchange Act. (Check one):
|
|
|
|
Large
accelerated
filer þ
|
Accelerated
filer o
|
Non-accelerated
filer o
|
Smaller
reporting
company o
|
(Do not check if a smaller reporting company)
Indicate by check mark whether the registrant is a shell company
(as defined in
Rule 12b-2
of the Exchange
Act). Yes o No þ
The number of outstanding shares of the registrants
Series A common stock, $0.0001 par value, as of
October 17, 2008 was 143,406,433.
CELANESE
CORPORATION
Form 10-Q
For the Quarterly Period Ended September 30, 2008
TABLE OF CONTENTS
2
CELANESE
CORPORATION AND SUBSIDIARIES
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended September 30,
|
|
|
Nine Months Ended September 30,
|
|
|
|
2008
|
|
|
2007
|
|
|
2008
|
|
|
2007
|
|
|
|
(in $ millions, except for per share data)
|
|
|
Net sales
|
|
|
1,823
|
|
|
|
1,573
|
|
|
|
5,537
|
|
|
|
4,684
|
|
Cost of sales
|
|
|
(1,490
|
)
|
|
|
(1,236
|
)
|
|
|
(4,390
|
)
|
|
|
(3,651
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Gross profit
|
|
|
333
|
|
|
|
337
|
|
|
|
1,147
|
|
|
|
1,033
|
|
Selling, general and administrative expenses
|
|
|
(142
|
)
|
|
|
(133
|
)
|
|
|
(416
|
)
|
|
|
(371
|
)
|
Amortization of intangible assets (primarily customer
relationships)
|
|
|
(19
|
)
|
|
|
(18
|
)
|
|
|
(58
|
)
|
|
|
(53
|
)
|
Research and development expenses
|
|
|
(18
|
)
|
|
|
(18
|
)
|
|
|
(59
|
)
|
|
|
(54
|
)
|
Other (charges) gains, net
|
|
|
(1
|
)
|
|
|
(12
|
)
|
|
|
(24
|
)
|
|
|
(118
|
)
|
Foreign exchange gain (loss), net
|
|
|
(1
|
)
|
|
|
|
|
|
|
3
|
|
|
|
|
|
Gain (loss) on disposition of businesses and assets, net
|
|
|
(1
|
)
|
|
|
(9
|
)
|
|
|
(1
|
)
|
|
|
(13
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating profit
|
|
|
151
|
|
|
|
147
|
|
|
|
592
|
|
|
|
424
|
|
Equity in net earnings of affiliates
|
|
|
19
|
|
|
|
24
|
|
|
|
46
|
|
|
|
65
|
|
Interest expense
|
|
|
(65
|
)
|
|
|
(63
|
)
|
|
|
(195
|
)
|
|
|
(196
|
)
|
Refinancing expense
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(256
|
)
|
Interest income
|
|
|
8
|
|
|
|
9
|
|
|
|
27
|
|
|
|
34
|
|
Dividend income cost investments
|
|
|
35
|
|
|
|
29
|
|
|
|
138
|
|
|
|
93
|
|
Other income (expense), net
|
|
|
4
|
|
|
|
(15
|
)
|
|
|
9
|
|
|
|
(30
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Earnings (loss) from continuing operations before tax and
minority interests
|
|
|
152
|
|
|
|
131
|
|
|
|
617
|
|
|
|
134
|
|
Income tax (provision) benefit
|
|
|
12
|
|
|
|
(1
|
)
|
|
|
(106
|
)
|
|
|
(6
|
)
|
Minority interests
|
|
|
|
|
|
|
|
|
|
|
1
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Earnings (loss) from continuing operations
|
|
|
164
|
|
|
|
130
|
|
|
|
512
|
|
|
|
128
|
|
Earnings (loss) from operation of discontinued operations
|
|
|
(8
|
)
|
|
|
|
|
|
|
(120
|
)
|
|
|
38
|
|
Gain (loss) on disposal of discontinued operations
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
47
|
|
Income tax (provision) benefit
|
|
|
2
|
|
|
|
(2
|
)
|
|
|
45
|
|
|
|
(1
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Earnings (loss) from discontinued operations
|
|
|
(6
|
)
|
|
|
(2
|
)
|
|
|
(75
|
)
|
|
|
84
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net earnings (loss)
|
|
|
158
|
|
|
|
128
|
|
|
|
437
|
|
|
|
212
|
|
Cumulative preferred stock dividends
|
|
|
(3
|
)
|
|
|
(2
|
)
|
|
|
(8
|
)
|
|
|
(7
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net earnings (loss) available to common shareholders
|
|
|
155
|
|
|
|
126
|
|
|
|
429
|
|
|
|
205
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Earnings (loss) per common share basic:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Continuing operations
|
|
|
1.09
|
|
|
|
0.85
|
|
|
|
3.36
|
|
|
|
0.78
|
|
Discontinued operations
|
|
|
(0.04
|
)
|
|
|
(0.01
|
)
|
|
|
(0.50
|
)
|
|
|
0.54
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net earnings (loss) basic
|
|
|
1.05
|
|
|
|
0.84
|
|
|
|
2.86
|
|
|
|
1.32
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Earnings (loss) per common share diluted:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Continuing operations
|
|
|
1.01
|
|
|
|
0.77
|
|
|
|
3.08
|
|
|
|
0.74
|
|
Discontinued operations
|
|
|
(0.04
|
)
|
|
|
(0.01
|
)
|
|
|
(0.45
|
)
|
|
|
0.49
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net earnings (loss) diluted
|
|
|
0.97
|
|
|
|
0.76
|
|
|
|
2.63
|
|
|
|
1.23
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted average shares basic:
|
|
|
147,063,241
|
|
|
|
150,154,309
|
|
|
|
149,976,915
|
|
|
|
155,423,930
|
|
Weighted average shares diluted:
|
|
|
162,911,689
|
|
|
|
167,410,047
|
|
|
|
166,008,010
|
|
|
|
172,115,966
|
|
See the accompanying notes to the unaudited interim consolidated
financial statements.
3
CELANESE
CORPORATION AND SUBSIDIARIES
|
|
|
|
|
|
|
|
|
|
|
As of
|
|
|
As of
|
|
|
|
September 30,
|
|
|
December 31,
|
|
|
|
2008
|
|
|
2007
|
|
|
|
(in $ millions,
|
|
|
|
except share amounts)
|
|
|
ASSETS
|
Current assets
|
|
|
|
|
|
|
|
|
Cash and cash equivalents
|
|
|
584
|
|
|
|
825
|
|
Receivables:
|
|
|
|
|
|
|
|
|
Trade third party and affiliates (net of allowance
for doubtful accounts 2008 and 2007: $18)
|
|
|
1,013
|
|
|
|
1,009
|
|
Other
|
|
|
346
|
|
|
|
437
|
|
Inventories
|
|
|
743
|
|
|
|
636
|
|
Deferred income taxes
|
|
|
68
|
|
|
|
70
|
|
Marketable securities, at fair value
|
|
|
17
|
|
|
|
46
|
|
Other assets
|
|
|
49
|
|
|
|
40
|
|
|
|
|
|
|
|
|
|
|
Total current assets
|
|
|
2,820
|
|
|
|
3,063
|
|
|
|
|
|
|
|
|
|
|
Investments
|
|
|
779
|
|
|
|
814
|
|
Property, plant and equipment (net of accumulated
depreciation 2008: $1,028; 2007: $838)
|
|
|
2,527
|
|
|
|
2,362
|
|
Deferred income taxes
|
|
|
69
|
|
|
|
10
|
|
Marketable securities, at fair value
|
|
|
202
|
|
|
|
209
|
|
Other assets
|
|
|
370
|
|
|
|
309
|
|
Goodwill
|
|
|
816
|
|
|
|
866
|
|
Intangible assets, net
|
|
|
389
|
|
|
|
425
|
|
|
|
|
|
|
|
|
|
|
Total assets
|
|
|
7,972
|
|
|
|
8,058
|
|
|
|
|
|
|
|
|
|
|
|
LIABILITIES AND SHAREHOLDERS EQUITY
|
Current liabilities
|
|
|
|
|
|
|
|
|
Short-term borrowings and current installments of long-term
debt third party and affiliates
|
|
|
302
|
|
|
|
272
|
|
Trade payables third party and affiliates
|
|
|
754
|
|
|
|
818
|
|
Other liabilities
|
|
|
561
|
|
|
|
888
|
|
Deferred income taxes
|
|
|
29
|
|
|
|
30
|
|
Income taxes payable
|
|
|
52
|
|
|
|
23
|
|
|
|
|
|
|
|
|
|
|
Total current liabilities
|
|
|
1,698
|
|
|
|
2,031
|
|
|
|
|
|
|
|
|
|
|
Long-term debt
|
|
|
3,318
|
|
|
|
3,284
|
|
Deferred income taxes
|
|
|
243
|
|
|
|
265
|
|
Uncertain tax positions
|
|
|
238
|
|
|
|
220
|
|
Benefit obligations
|
|
|
651
|
|
|
|
696
|
|
Other liabilities
|
|
|
793
|
|
|
|
495
|
|
Minority interests
|
|
|
2
|
|
|
|
5
|
|
Commitments and contingencies
|
|
|
|
|
|
|
|
|
Shareholders equity
|
|
|
|
|
|
|
|
|
Preferred stock, $0.01 par value, 100,000,000 shares
authorized (2008 and 2007: 9,600,000 issued and outstanding)
|
|
|
|
|
|
|
|
|
Series A common stock, $0.0001 par value,
400,000,000 shares authorized (2008: 164,008,119 issued and
143,406,433 outstanding; 2007: 162,941,287 issued and
152,102,801 outstanding)
|
|
|
|
|
|
|
|
|
Series B common stock, $0.0001 par value,
100,000,000 shares authorized (2008 and 2007: 0 shares
issued and outstanding)
|
|
|
|
|
|
|
|
|
Treasury stock, at cost (2008:
20,601,686 shares; 2007: 10,838,486 shares)
|
|
|
(781
|
)
|
|
|
(403
|
)
|
Additional paid-in capital
|
|
|
492
|
|
|
|
469
|
|
Retained earnings
|
|
|
1,210
|
|
|
|
799
|
|
Accumulated other comprehensive income (loss), net
|
|
|
108
|
|
|
|
197
|
|
|
|
|
|
|
|
|
|
|
Total shareholders equity
|
|
|
1,029
|
|
|
|
1,062
|
|
|
|
|
|
|
|
|
|
|
Total liabilities and shareholders equity
|
|
|
7,972
|
|
|
|
8,058
|
|
|
|
|
|
|
|
|
|
|
See the accompanying notes to the unaudited interim consolidated
financial statements.
4
CELANESE
CORPORATION AND SUBSIDIARIES
SHAREHOLDERS
EQUITY AND COMPREHENSIVE INCOME (LOSS)
|
|
|
|
|
|
|
|
|
|
|
Nine Months Ended
|
|
|
September 30, 2008
|
|
|
Shares Outstanding
|
|
Amount
|
|
|
(in $ millions, except share data)
|
|
Preferred stock
|
|
|
|
|
|
|
|
|
Balance as of the beginning of the period
|
|
|
9,600,000
|
|
|
|
|
|
Issuance of preferred stock
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance as of the end of the period
|
|
|
9,600,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Series A common stock
|
|
|
|
|
|
|
|
|
Balance as of the beginning of the period
|
|
|
152,102,801
|
|
|
|
|
|
Stock option exercises
|
|
|
1,056,368
|
|
|
|
|
|
Purchases of treasury stock
|
|
|
(9,763,200
|
)
|
|
|
|
|
Issuance of stock awards
|
|
|
10,464
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance as of the end of the period
|
|
|
143,406,433
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Treasury stock
|
|
|
|
|
|
|
|
|
Balance as of the beginning of the period
|
|
|
10,838,486
|
|
|
|
(403
|
)
|
Purchases of treasury stock, including related fees
|
|
|
9,763,200
|
|
|
|
(378
|
)
|
|
|
|
|
|
|
|
|
|
Balance as of the end of the period
|
|
|
20,601,686
|
|
|
|
(781
|
)
|
|
|
|
|
|
|
|
|
|
Additional paid-in capital
|
|
|
|
|
|
|
|
|
Balance as of the beginning of the period
|
|
|
|
|
|
|
469
|
|
Indemnification of demerger liability
|
|
|
|
|
|
|
2
|
|
Stock-based compensation
|
|
|
|
|
|
|
11
|
|
Stock option exercises, net of tax
|
|
|
|
|
|
|
10
|
|
|
|
|
|
|
|
|
|
|
Balance as of the end of the period
|
|
|
|
|
|
|
492
|
|
|
|
|
|
|
|
|
|
|
Retained earnings
|
|
|
|
|
|
|
|
|
Balance as of the beginning of the period
|
|
|
|
|
|
|
799
|
|
Net earnings (loss)
|
|
|
|
|
|
|
437
|
|
Series A common stock dividends
|
|
|
|
|
|
|
(18
|
)
|
Preferred stock dividends
|
|
|
|
|
|
|
(8
|
)
|
|
|
|
|
|
|
|
|
|
Balance as of the end of the period
|
|
|
|
|
|
|
1,210
|
|
|
|
|
|
|
|
|
|
|
Accumulated other comprehensive income (loss), net
|
|
|
|
|
|
|
|
|
Balance as of the beginning of the period
|
|
|
|
|
|
|
197
|
|
Unrealized gain (loss) on securities
|
|
|
|
|
|
|
(19
|
)
|
Foreign currency translation
|
|
|
|
|
|
|
(67
|
)
|
Unrealized gain (loss) on interest rate swaps
|
|
|
|
|
|
|
(1
|
)
|
Pension and postretirement benefits
|
|
|
|
|
|
|
(2
|
)
|
|
|
|
|
|
|
|
|
|
Balance as of the end of the period
|
|
|
|
|
|
|
108
|
|
|
|
|
|
|
|
|
|
|
Total shareholders equity
|
|
|
|
|
|
|
1,029
|
|
|
|
|
|
|
|
|
|
|
Comprehensive income (loss)
|
|
|
|
|
|
|
|
|
Net earnings (loss)
|
|
|
|
|
|
|
437
|
|
Other comprehensive income (loss), net of tax:
|
|
|
|
|
|
|
|
|
Unrealized gain (loss) on securities
|
|
|
|
|
|
|
(19
|
)
|
Foreign currency translation
|
|
|
|
|
|
|
(67
|
)
|
Unrealized gain (loss) on interest rate swaps
|
|
|
|
|
|
|
(1
|
)
|
Pension and postretirement benefits
|
|
|
|
|
|
|
(2
|
)
|
|
|
|
|
|
|
|
|
|
Total comprehensive income (loss), net of tax
|
|
|
|
|
|
|
348
|
|
|
|
|
|
|
|
|
|
|
See the accompanying notes to the unaudited interim consolidated
financial statements.
5
CELANESE
CORPORATION AND SUBSIDIARIES
|
|
|
|
|
|
|
|
|
|
|
Nine Months Ended
|
|
|
September 30,
|
|
|
2008
|
|
2007
|
|
|
(in $ millions)
|
|
Operating activities
|
|
|
|
|
|
|
|
|
Net earnings (loss)
|
|
|
437
|
|
|
|
212
|
|
Adjustments to reconcile net earnings (loss) to net cash
provided by operating activities:
|
|
|
|
|
|
|
|
|
Other (charges) gains, net of amounts used
|
|
|
19
|
|
|
|
17
|
|
Depreciation, amortization and accretion
|
|
|
272
|
|
|
|
238
|
|
Deferred income taxes, net
|
|
|
(5
|
)
|
|
|
(59
|
)
|
(Gain) loss on disposition of businesses and assets, net
|
|
|
2
|
|
|
|
(31
|
)
|
Refinancing expense
|
|
|
|
|
|
|
256
|
|
Other, net
|
|
|
25
|
|
|
|
(2
|
)
|
Operating cash provided by (used in) discontinued operations
|
|
|
10
|
|
|
|
(92
|
)
|
Changes in operating assets and liabilities:
|
|
|
|
|
|
|
|
|
Trade receivables third party and affiliates, net
|
|
|
(14
|
)
|
|
|
(34
|
)
|
Inventories
|
|
|
(120
|
)
|
|
|
25
|
|
Other assets
|
|
|
58
|
|
|
|
90
|
|
Trade payables third party and affiliates
|
|
|
(43
|
)
|
|
|
(98
|
)
|
Other liabilities
|
|
|
(296
|
)
|
|
|
(243
|
)
|
|
|
|
|
|
|
|
|
|
Net cash provided by operating activities
|
|
|
345
|
|
|
|
279
|
|
|
|
|
|
|
|
|
|
|
Investing activities
|
|
|
|
|
|
|
|
|
Capital expenditures on property, plant and equipment
|
|
|
(212
|
)
|
|
|
(217
|
)
|
Acquisitions and related fees, net of cash acquired
|
|
|
(1
|
)
|
|
|
(269
|
)
|
Proceeds from sale of businesses and assets, net
|
|
|
7
|
|
|
|
682
|
|
Deferred proceeds on Ticona Kelsterbach plant relocation
|
|
|
311
|
|
|
|
|
|
Capital expenditures related to Ticona Kelsterbach plant
relocation
|
|
|
(122
|
)
|
|
|
(13
|
)
|
Proceeds from sale of marketable securities
|
|
|
147
|
|
|
|
39
|
|
Purchases of marketable securities
|
|
|
(128
|
)
|
|
|
(39
|
)
|
Changes in restricted cash
|
|
|
|
|
|
|
46
|
|
Settlement of cross currency swap agreement
|
|
|
(93
|
)
|
|
|
|
|
Other, net
|
|
|
(78
|
)
|
|
|
(33
|
)
|
|
|
|
|
|
|
|
|
|
Net cash provided by (used in) investing activities
|
|
|
(169
|
)
|
|
|
196
|
|
|
|
|
|
|
|
|
|
|
Financing activities
|
|
|
|
|
|
|
|
|
Short-term borrowings (repayments), net
|
|
|
8
|
|
|
|
18
|
|
Proceeds from long-term debt
|
|
|
13
|
|
|
|
2,885
|
|
Repayments of long-term debt
|
|
|
(31
|
)
|
|
|
(3,045
|
)
|
Refinancing costs
|
|
|
|
|
|
|
(240
|
)
|
Purchases of treasury stock, including related fees
|
|
|
(378
|
)
|
|
|
(403
|
)
|
Stock option exercises
|
|
|
18
|
|
|
|
51
|
|
Dividend payments on Series A common stock and preferred
stock
|
|
|
(26
|
)
|
|
|
(26
|
)
|
Other, net
|
|
|
(6
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net cash used in financing activities
|
|
|
(402
|
)
|
|
|
(760
|
)
|
Exchange rate effects on cash and cash equivalents
|
|
|
(15
|
)
|
|
|
25
|
|
|
|
|
|
|
|
|
|
|
Net increase (decrease) in cash and cash equivalents
|
|
|
(241
|
)
|
|
|
(260
|
)
|
Cash and cash equivalents at beginning of period
|
|
|
825
|
|
|
|
791
|
|
|
|
|
|
|
|
|
|
|
Cash and cash equivalents at end of period
|
|
|
584
|
|
|
|
531
|
|
|
|
|
|
|
|
|
|
|
See the accompanying notes to the unaudited interim consolidated
financial statements.
6
CELANESE
CORPORATION AND SUBSIDIARIES
|
|
1.
|
Description
of the Company and Basis of Presentation
|
Description
of the Company
Celanese Corporation and its subsidiaries (collectively the
Company) is a leading global integrated chemical and
advanced materials company. The Companys business involves
processing chemical raw materials, such as methanol, carbon
monoxide and ethylene, and natural products, including wood
pulp, into value-added chemicals, thermoplastic polymers and
other chemical-based products.
Basis
of Presentation
In this Quarterly Report on
Form 10-Q,
the term Celanese US refers to the Companys
subsidiary, Celanese US Holdings LLC, a Delaware limited
liability company, and not its subsidiaries. The term
Purchaser refers to the Companys subsidiary,
Celanese Europe Holding GmbH & Co. KG, a German
limited partnership, and not its subsidiaries, except where
otherwise indicated. The term Advisor refers to
Blackstone Management Partners, an affiliate of The Blackstone
Group. The term CAG refers to Celanese GmbH,
formerly known as Celanese AG, its consolidated subsidiaries,
its non-consolidated subsidiaries, ventures and other
investments. The term Original Shareholders refers,
collectively, to Blackstone Capital Partners (Cayman) Ltd. 1,
Blackstone Capital Partners (Cayman) Ltd. 2, Blackstone Capital
Partners (Cayman) Ltd. 3 and BA Capital Investors Sidecar Fund,
L.P.
The unaudited interim consolidated financial statements for the
three and nine months ended September 30, 2008 and 2007
contained in this Quarterly Report were prepared in accordance
with accounting principles generally accepted in the United
States of America (US GAAP) for all periods
presented. The unaudited interim consolidated financial
statements and other financial information included in this
Quarterly Report, unless otherwise specified, have been
presented to separately show the effects of discontinued
operations.
In the opinion of management, the accompanying unaudited
consolidated balance sheets and related unaudited interim
consolidated statements of operations, cash flows and
shareholders equity and comprehensive income (loss)
include all adjustments, consisting only of normal recurring
items necessary for their fair presentation in conformity with
US GAAP. Certain information and footnote disclosures normally
included in financial statements prepared in accordance with US
GAAP have been condensed or omitted in accordance with rules and
regulations of the Securities and Exchange Commission
(SEC). These unaudited interim consolidated
financial statements should be read in conjunction with the
Celanese Corporation and Subsidiaries consolidated financial
statements as of and for the year ended December 31, 2007,
as filed on February 29, 2008 with the SEC as part of the
Companys Annual Report on
Form 10-K
(the 2007
Form 10-K).
Operating results for the three and nine months ended
September 30, 2008 are not necessarily indicative of the
results to be expected for the entire year.
Estimates
and Assumptions
The preparation of consolidated financial statements in
conformity with US GAAP requires management to make estimates
and assumptions that affect the reported amounts of assets and
liabilities, disclosure of contingent assets and liabilities at
the date of the consolidated financial statements and the
reported amounts of revenues, expenses and allocated charges
during the reporting period. Significant estimates pertain to
impairments of goodwill, intangible assets and other long-lived
assets, purchase price allocations, restructuring costs and
other (charges) gains, net, income taxes, pension and other
postretirement benefits, asset retirement obligations,
environmental liabilities and loss contingencies, among others.
Actual results could differ from those estimates.
Reclassifications
The Company has reclassified certain prior period amounts to
conform to the current periods presentation.
7
CELANESE
CORPORATION AND SUBSIDIARIES
NOTES TO
THE UNAUDITED INTERIM CONSOLIDATED
FINANCIAL
STATEMENTS (Continued)
|
|
2.
|
Recent
Accounting Pronouncements
|
In December 2007, the Financial Accounting Standards Board
(FASB) issued Statement of Financial Accounting
Standards (SFAS) No. 160, Noncontrolling
Interests in Consolidated Financial Statements an
amendment of ARB 51 (SFAS No. 160) to
establish accounting and reporting standards for the
noncontrolling interest in a subsidiary and for the
deconsolidation of a subsidiary. It clarifies that a
noncontrolling interest in a subsidiary is an ownership interest
in the consolidated entity that should be reported as equity in
the consolidated financial statements and establishes a single
method of accounting for changes in a parents ownership
interest in a subsidiary that does not result in
deconsolidation. SFAS No. 160 is effective for the
Company on January 1, 2009. This standard will not have a
material impact on the Companys financial position,
results of operations or cash flows.
In March 2008, the FASB issued SFAS No. 161,
Disclosures about Derivative Instruments and Hedging
Activities, an amendment of FASB Statement No. 133
(SFAS No. 161). SFAS No. 161
requires enhanced disclosures about a companys derivative
and hedging activities. These enhanced disclosures will discuss:
(a) how and why a company uses derivative instruments,
(b) how derivative instruments and related hedged items are
accounted for under FASB Statement No. 133 and its related
interpretations and (c) how derivative instruments and
related hedged items affect a companys financial position,
results of operations and cash flows. SFAS No. 161 is
effective for the Company on January 1, 2009. This standard
will have no impact on the Companys financial position,
results of operations or cash flows.
In April 2008, the FASB issued FASB Staff Position
(FSP)
FAS No. 142-3,
Determination of the Useful Life of Intangible Assets
(FSP
FAS No. 142-3).
FSP
FAS No. 142-3
amends the factors that should be considered in developing
renewal or extension assumptions used to determine the useful
life of a recognized intangible asset under
SFAS No. 142, Goodwill and Other Intangible
Assets. The intent of this FSP is to improve the consistency
between the useful life of a recognized intangible asset and the
period of expected cash flows used to measure the fair value of
the asset under SFAS No. 141 (revised 2007),
Business Combinations, and other US GAAP. FSP
FAS No. 142-3
is effective for the Company on January 1, 2009. This
standard will have no material impact on the Companys
financial position, results of operations or cash flows.
In May 2008, the FASB issued SFAS No. 162, The
Hierarchy of Generally Accepted Accounting Principles,
(SFAS No. 162), which becomes effective
November 15, 2008. SFAS No. 162 identifies the
sources of accounting principles and the framework for selecting
the principles to be used in the preparation of financial
statements of nongovernmental entities that are presented in
conformity with US GAAP. This standard will have no impact on
the Companys financial position, results of operations or
cash flows.
In October 2008, the FASB issued FASB Staff Position
No. 157-3, Determining the Fair Value of a Financial
Asset When the Market for That Asset Is Not Active
(FSP No. 157-3), to provide guidance on
determining the fair value of financial instruments in inactive
markets. FSP No. 157-3 became effective for the Company
upon issuance, and had no material impact on the Companys
financial position, results of operations or cash flows.
|
|
3.
|
Acquisitions,
Ventures and Divestitures
|
Acquisitions
On January 31, 2007, the Company completed the acquisition
of the cellulose acetate flake, tow and film businesses of
Acetate Products Limited, a subsidiary of Corsadi B.V. The
purchase price for the transaction was approximately
£57 million ($112 million), in addition to direct
acquisition costs of approximately £4 million
($7 million). As contemplated prior to closing of the
acquisition, the Company closed the acquired tow production
plant at Little Heath, United Kingdom in September 2007. In
accordance with the Companys sponsor services agreement
dated January 26, 2005, as amended, the Company paid the
Advisor $1 million in connection with the acquisition. The
acquired business is included in the Companys Consumer
Specialties segment.
8
CELANESE
CORPORATION AND SUBSIDIARIES
NOTES TO
THE UNAUDITED INTERIM CONSOLIDATED
FINANCIAL
STATEMENTS (Continued)
On April 6, 2004, the Company acquired 84% of CAG. During
2005, the Company acquired an additional 14% of CAG. On
May 30, 2006, CAGs shareholders approved a transfer
to the Purchaser of all shares owned by minority shareholders
against payment of cash compensation in the amount
of 66.99 per share (the Squeeze-Out). As
a result of the effective registration of the Squeeze-Out in the
commercial register in Germany in December 2006, the Company
acquired the remaining 2% of CAG in January 2007. The
Companys current ownership percentage in CAG is 100%.
Ventures
In March 2007, the Company entered into a strategic partnership
with Accsys Technologies PLC (Accsys), and its
subsidiary, Titan Wood Ltd., to become the exclusive supplier of
acetyl products to Titan Woods technology licensees for
use in wood acetylation. In conjunction with this partnership,
in May 2007, the Company acquired 8,115,883 shares of
Accsys common stock representing approximately 5.45% of
the total voting shares of Accsys for 22 million
($30 million). The investment was treated as an
available-for-sale security and was included as a component of
current Marketable securities, at fair value, in the
Companys consolidated balance sheet. In November 2007, the
Company and Accsys announced an agreement to amend their
business arrangements such that each company will have a
nonexclusive at-will trading and supply relationship
to give both companies greater flexibility. As part of this
amendment, the Company subsequently sold all of its shares of
Accsys stock for approximately 20 million
($30 million), which resulted in a cumulative loss of
$3 million.
Divestitures/Discontinued
Operations
In connection with the Companys strategy to optimize its
portfolio and divest non-core operations, the Company announced
on December 13, 2006 its agreement to sell its Acetyl
Intermediates segments oxo products and derivatives
businesses, including European Oxo GmbH (EOXO), a
50/50
venture between CAG and Degussa AG (Degussa), to
Advent International, for a purchase price
of 480 million ($636 million) subject to
final agreement adjustments and the successful exercise of the
Companys option to purchase Degussas 50% interest in
EOXO. On February 23, 2007, the option was exercised and
the Company acquired Degussas interest in the venture for
a purchase price of 30 million
($39 million), in addition to 22 million
($29 million) paid to extinguish EOXOs debt upon
closing of the transaction. The Company completed the sale of
its oxo products and derivatives businesses, including the
acquired 50% interest in EOXO, on February 28, 2007. The
sale included the oxo and derivatives businesses at the
Oberhausen, Germany, and Bay City, Texas facilities as well as
portions of the Companys Bishop, Texas facility. Also
included were EOXOs facilities within the Oberhausen and
Marl, Germany plants. The former oxo and derivatives businesses
acquired by Advent International were renamed Oxea. Taking into
account agreed deductions by the buyer for pension and other
employee benefits and various costs for separation activities,
the Company received proceeds of
approximately 443 million ($585 million) at
closing. The transaction resulted in the recognition of a
$47 million pre-tax gain, which includes certain working
capital and other adjustments, in 2007. Due to certain
lease-back arrangements between the Company and the buyer and
related environmental obligations of the Company, approximately
$51 million of the transaction proceeds attributable to the
fair value of the underlying land at Oberhausen
(36 million) and Bay City ($1 million) is
included in deferred proceeds in noncurrent Other liabilities,
and divested land with a book value of $14 million
(10 million at Oberhausen and $1 million at Bay
City) remains in property, plant and equipment, net, in the
consolidated balance sheets.
The Company concluded, based on the nature and limited projected
magnitude of the continuing business relationship between the
Company and Oxea, that the divestiture of the oxo products and
derivatives businesses should be accounted for as discontinued
operations. Third party sales of $5 million for the nine
months ended September 30, 2007 would have been eliminated
upon consolidation were the divestiture not accounted for as
discontinued operations.
In accordance with the Companys sponsor services agreement
dated January 26, 2005, as amended, the Company paid the
Advisor $6 million in connection with the sale of the oxo
products and derivatives businesses.
9
CELANESE
CORPORATION AND SUBSIDIARIES
NOTES TO
THE UNAUDITED INTERIM CONSOLIDATED
FINANCIAL
STATEMENTS (Continued)
During the second quarter of 2007, the Company discontinued its
Edmonton, Alberta, Canada methanol operations, which were
included in the Acetyl Intermediates segment. As a result, the
earnings (loss) related to the Edmonton methanol operations are
accounted for as discontinued operations.
Net sales and gross profit (loss) for discontinued operations
for the three months ended September 30, 2007 were
$0 million and $(1) million, respectively. Net sales
and gross profit for discontinued operations for the nine months
ended September 30, 2007 were $197 million and
$46 million, respectively.
Asset
Sales
In July 2007, the Company reached an agreement with
Babcock & Brown, a worldwide investment firm which
specializes in real estate and utilities development, to sell
the Companys Pampa, Texas, facility. The Company will
maintain its chemical operations at the site until at least
2009. Proceeds received upon certain milestone events will be
treated as deferred proceeds and included in noncurrent Other
liabilities in the Companys consolidated balance sheets
until the transaction is complete (expected to be in 2010), as
defined in the sales agreement. These operations are included in
the Companys Acetyls Intermediates segment. In September
2008, the Company determined that two of the milestone events,
which are outside of the Companys control, are unlikely to
be achieved. The Company performed a discounted cash flow
analysis which resulted in a $21 million long-lived asset
impairment charge to Other (charges) gains, net, in the
consolidated statements of operations during the three months
ended September 30, 2008 (see Note 12).
In August 2007, the Company sold its Films business of AT
Plastics, located in Edmonton and Westlock, Alberta, Canada, to
British Polythene Industries PLC (BPI) for
$12 million. The Films business manufactures products for
the agricultural, horticultural and construction industries. The
Company recorded a loss on the sale of $7 million during
the three and nine months ended September 30, 2007. The
Company maintained ownership of the Polymers business of AT
Plastics, which concentrates on the development and supply of
specialty resins and compounds. AT Plastics is included in the
Companys Industrial Specialties segment. The Company
concluded that the sale of the Films business of AT Plastics is
not a discontinued operation due to the level of continuing cash
flows between the Films business and AT Plastics Polymers
business subsequent to the sale. Under the terms of the purchase
agreement, the Company entered into a two year sales agreement
to continue selling product to BPI through August 2009.
In May 2008, shareholders of the Companys Koper, Slovenia
legal entity voted to approve the April 2008 decision by the
Company to permanently shut down this emulsions production site.
The decision to shut down the site resulted in employee
severance of less than $1 million which is included in
Other (charges) gains, net, in the consolidated statements of
operations during the nine months ended September 30, 2008.
Currently, the facility is idle and the existing fixed assets,
including machinery and equipment, buildings and land are being
marketed for sale. The net book value of the assets held for
sale is approximately $1 million. The Koper, Slovenia legal
entity is included in the Companys Industrial Specialties
segment.
In July 2008, the Company sold its 55.46% interest in Derivados
Macroquimicos S.A. de C.V. (DEMACSA) for proceeds of
$3 million. DEMACSA produces cellulose ethers at an
industrial complex in Zacapu, Michoacan, Mexico and is included
in the Companys Acetyl Intermediates segment. In June
2008, the Company recorded an impairment charge of
$1 million. As a result, the proceeds from the sale
approximated the carrying value of DEMACSA on the date of the
sale. The Company concluded the sale of DEMACSA is not a
discontinued operation due to certain forms of continuing
involvement between the Company and DEMACSA subsequent to the
sale.
Cost
Method Investments
In February 2007, the Company wrote-off its
remaining 1 million ($1 million) cost
investment in European Pipeline Development Company B.V.
(EPDC) which was included in the Companys
Acetyl Intermediates
10
CELANESE
CORPORATION AND SUBSIDIARIES
NOTES TO
THE UNAUDITED INTERIM CONSOLIDATED
FINANCIAL
STATEMENTS (Continued)
segment and expensed 7 million ($9 million)
associated with contingent liabilities that became payable due
to the Companys decision to exit the pipeline development
project. In June 2008, the outstanding contingent liabilities
were resolved and the Company recognized a gain
of 2 million ($2 million), included in
Other income (expense), net, in the consolidated statements of
operations to remove the remaining accrual. The investment in
EPDC related to the construction of a pipeline system, solely
dedicated to the transportation of propylene, which was to
connect Rotterdam via Antwerp, Netherlands, with the
Companys Oberhausen and Marl production facilities in
Germany. However, on February 15, 2007, EPDC shareholders
voted to cease the pipeline project as originally envisaged and
go into liquidation. The Company was a 12.5% shareholder of EPDC.
|
|
|
|
|
|
|
|
|
|
|
As of
|
|
|
As of
|
|
|
|
September 30,
|
|
|
December 31,
|
|
|
|
2008
|
|
|
2007
|
|
|
|
(in $ millions)
|
|
|
Finished goods
|
|
|
580
|
|
|
|
500
|
|
Work-in-process
|
|
|
31
|
|
|
|
29
|
|
Raw materials and supplies
|
|
|
132
|
|
|
|
107
|
|
|
|
|
|
|
|
|
|
|
Total inventories
|
|
|
743
|
|
|
|
636
|
|
|
|
|
|
|
|
|
|
|
|
|
5.
|
Goodwill
and Intangible Assets, Net
|
Goodwill
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Advanced
|
|
|
|
|
|
|
|
|
|
|
Engineered
|
|
Consumer
|
|
Industrial
|
|
Acetyl
|
|
|
|
|
Materials
|
|
Specialties
|
|
Specialties
|
|
Intermediates
|
|
Total
|
|
|
(in $ millions)
|
|
As of December 31, 2007
|
|
|
277
|
|
|
|
264
|
|
|
|
47
|
|
|
|
278
|
|
|
|
866
|
|
Adjustments to pre-acquisition tax uncertainties
|
|
|
(6
|
)
|
|
|
(3
|
)
|
|
|
(5
|
)
|
|
|
(19
|
)
|
|
|
(33
|
)
|
Exchange rate changes
|
|
|
(5
|
)
|
|
|
(7
|
)
|
|
|
|
|
|
|
(5
|
)
|
|
|
(17
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
As of September 30, 2008
|
|
|
266
|
|
|
|
254
|
|
|
|
42
|
|
|
|
254
|
|
|
|
816
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
In connection with the Companys annual goodwill impairment
test, the Company did not record an impairment charge to
goodwill during the nine months ended September 30, 2008.
11
CELANESE
CORPORATION AND SUBSIDIARIES
NOTES TO
THE UNAUDITED INTERIM CONSOLIDATED
FINANCIAL
STATEMENTS (Continued)
Intangible
Assets, Net
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Trademarks and
|
|
Customer
|
|
Developed
|
|
|
|
|
|
|
Licenses
|
|
Tradenames
|
|
Relationships
|
|
Technology
|
|
Other
|
|
Total
|
|
|
(in $ millions)
|
|
Gross Asset Value
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
As of December 31, 2007
|
|
|
|
|
|
|
85
|
|
|
|
562
|
|
|
|
12
|
|
|
|
12
|
|
|
|
671
|
|
Additions(1)
|
|
|
28
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
28
|
|
Exchange rate changes
|
|
|
1
|
|
|
|
(2
|
)
|
|
|
(13
|
)
|
|
|
|
|
|
|
|
|
|
|
(14
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
As of September 30, 2008
|
|
|
29
|
|
|
|
83
|
|
|
|
549
|
|
|
|
12
|
|
|
|
12
|
|
|
|
685
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Accumulated Amortization
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
As of December 31, 2007
|
|
|
|
|
|
|
|
|
|
|
(228
|
)
|
|
|
(9
|
)
|
|
|
(9
|
)
|
|
|
(246
|
)
|
Amortization
|
|
|
(2
|
)
|
|
|
|
|
|
|
(54
|
)
|
|
|
(1
|
)
|
|
|
(1
|
)
|
|
|
(58
|
)
|
Exchange rate changes
|
|
|
|
|
|
|
|
|
|
|
8
|
|
|
|
|
|
|
|
|
|
|
|
8
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
As of September 30, 2008
|
|
|
(2
|
)
|
|
|
|
|
|
|
(274
|
)
|
|
|
(10
|
)
|
|
|
(10
|
)
|
|
|
(296
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net book value as of September 30, 2008
|
|
|
27
|
|
|
|
83
|
|
|
|
275
|
|
|
|
2
|
|
|
|
2
|
|
|
|
389
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1) |
|
Acquisition of a sole and exclusive license to patents and
patent applications related to acetic acid. |
Aggregate amortization expense for intangible assets with finite
lives during the three months ended September 30, 2008 and
2007 was $19 million and $18 million, respectively.
Aggregate amortization expense for intangible assets with finite
lives during the nine months ended September 30, 2008 and
2007 was $58 million and $53 million, respectively.
Estimated amortization expense for the succeeding five fiscal
years is $63 million in 2009, $55 million in 2010,
$51 million in 2011, $39 million in 2012 and
$24 million in 2013.
In connection with the Companys annual indefinite-lived
intangible assets impairment test, the Company did not record an
impairment to indefinite-lived intangible assets during the nine
months September 30, 2008.
12
CELANESE
CORPORATION AND SUBSIDIARIES
NOTES TO
THE UNAUDITED INTERIM CONSOLIDATED
FINANCIAL
STATEMENTS (Continued)
|
|
|
|
|
|
|
|
|
|
|
As of
|
|
As of
|
|
|
September 30,
|
|
December 31,
|
|
|
2008
|
|
2007
|
|
|
(in $ millions)
|
|
Short-term borrowings and current installments of long-term
debt third party and affiliates
|
|
|
|
|
|
|
|
|
Current installments of long-term debt
|
|
|
72
|
|
|
|
44
|
|
Short-term borrowings, principally comprised of amounts due to
affiliates
|
|
|
230
|
|
|
|
228
|
|
|
|
|
|
|
|
|
|
|
Total short-term borrowings and current installments of
long-term debt third party and affiliates
|
|
|
302
|
|
|
|
272
|
|
|
|
|
|
|
|
|
|
|
Long-term debt
|
|
|
|
|
|
|
|
|
Senior Credit Facilities: Term Loan facility due 2014
|
|
|
2,817
|
|
|
|
2,855
|
|
Term notes 7.125%, due 2009
|
|
|
14
|
|
|
|
14
|
|
Pollution control and industrial revenue bonds, interest rates
ranging from 5.7% to 6.7%, due at various dates through 2030
|
|
|
181
|
|
|
|
181
|
|
Obligations under capital leases and other secured and unsecured
borrowings due at various dates through 2023
|
|
|
191
|
|
|
|
110
|
|
Other bank obligations, interest rates ranging from 5.9% to
7.1%, due at various dates through 2014
|
|
|
187
|
|
|
|
168
|
|
|
|
|
|
|
|
|
|
|
Subtotal
|
|
|
3,390
|
|
|
|
3,328
|
|
Less: Current installments of long-term debt
|
|
|
72
|
|
|
|
44
|
|
|
|
|
|
|
|
|
|
|
Total long-term debt
|
|
|
3,318
|
|
|
|
3,284
|
|
|
|
|
|
|
|
|
|
|
Senior
Credit Facilities
The Companys senior credit agreement consists of
$2,280 million of US dollar-denominated
and 400 million of Euro-denominated term loans
due 2014, a $650 million revolving credit facility
terminating in 2013 and a $228 million credit-linked
revolving facility terminating in 2014. Borrowings under the
senior credit agreement bear interest at a variable interest
rate based on LIBOR (for US dollars) or EURIBOR (for Euros), as
applicable, or, for US dollar-denominated loans under certain
circumstances, a base rate, in each case plus an applicable
margin. The applicable margin for the term loans and any loans
under the credit-linked revolving facility is 1.75%, subject to
potential reductions as defined in the senior credit agreement.
As of September 30, 2008, the applicable margin was 1.5%
and continues to be subject to potential adjustments as defined
in the senior credit agreement. The term loans under the senior
credit agreement are subject to amortization at 1% of the
initial principal amount per annum, payable quarterly. The
remaining principal amount of the term loans is due on
April 2, 2014.
As of September 30, 2008, there were no outstanding
borrowings or letters of credit issued under the revolving
credit facility; accordingly, $650 million remained
available for borrowing. As of September 30, 2008, there
were $92 million of letters of credit issued under the
credit-linked revolving facility and $136 million remained
available for borrowing.
The senior credit agreement is guaranteed by Celanese Holdings
LLC, a subsidiary of Celanese Corporation, and certain domestic
subsidiaries of Celanese US, and is secured by a lien on
substantially all assets of Celanese US and such guarantors,
subject to certain agreed exceptions, pursuant to the Guarantee
and Collateral Agreement, dated as of April 2, 2007, by and
among Celanese Holdings LLC, Celanese US, certain subsidiaries
of Celanese US and Deutsche Bank AG, New York Branch, as
Administrative Agent and as Collateral Agent.
The Company is in compliance with all of the covenants related
to its debt agreements as of September 30, 2008.
13
CELANESE
CORPORATION AND SUBSIDIARIES
NOTES TO
THE UNAUDITED INTERIM CONSOLIDATED
FINANCIAL
STATEMENTS (Continued)
Debt
Refinancing
In March 2007, the Company announced a comprehensive
recapitalization plan to refinance its debt and repurchase
shares. On April 2, 2007, the Company, through certain of
its subsidiaries, entered into a new senior credit agreement.
Proceeds from the new senior credit agreement, together with
available cash, were used to retire the Companys
$2,454 million amended and restated (January
2005) senior credit facilities, which consisted of
$1,626 million in term loans due 2011, a $600 million
revolving credit facility terminating in 2009 and a
$228 million credit-linked revolving facility terminating
in 2009, and to retire all of the Companys
9.625% senior subordinated notes due 2014 and
10.375% senior subordinated notes due 2014 (the
Senior Subordinated Notes) and 10% senior
discount notes due 2014 and 10.5% senior discount notes due
2014 (the Senior Discount Notes) as discussed below.
On March 6, 2007, the Company commenced cash tender offers
(the Tender Offers) with respect to any and all of
the Senior Discount Notes, and any and all of the Senior
Subordinated Notes. The Tender Offers expired on April 2,
2007. Substantially all of the Senior Discount Notes and Senior
Subordinated Notes were tendered in conjunction with the Tender
Offers. The remaining outstanding Senior Discount Notes and
Senior Subordinated Notes not tendered in conjunction with the
Tender Offers were redeemed by the Company in May 2007 through
optional redemption allowed in the indentures.
As a result of the refinancing, the Company incurred premiums
paid on early redemption of debt, accelerated amortization and
other refinancing expense. The components of refinancing expense
are as follows:
|
|
|
|
|
|
|
Nine Months
|
|
|
|
Ended
|
|
|
|
September 30, 2007
|
|
|
|
(in $ millions)
|
|
|
Premiums paid on early redemption of debt
|
|
|
207
|
|
Accelerated amortization of premiums and deferred financing
costs on early redemption and prepayment of debt
|
|
|
33
|
|
Debt issuance costs and other
|
|
|
16
|
|
|
|
|
|
|
Total refinancing expense
|
|
|
256
|
|
|
|
|
|
|
The components of current Other liabilities are as follows:
|
|
|
|
|
|
|
|
|
|
|
As of
|
|
|
As of
|
|
|
|
September 30,
|
|
|
December 31,
|
|
|
|
2008
|
|
|
2007
|
|
|
|
(in $ millions)
|
|
|
Salaries and benefits
|
|
|
128
|
|
|
|
157
|
|
Environmental
|
|
|
17
|
|
|
|
19
|
|
Restructuring
|
|
|
36
|
|
|
|
40
|
|
Insurance
|
|
|
36
|
|
|
|
41
|
|
Sorbates antitrust actions
|
|
|
1
|
|
|
|
170
|
|
Asset retirement obligations
|
|
|
9
|
|
|
|
16
|
|
Derivatives
|
|
|
28
|
|
|
|
129
|
|
Other
|
|
|
306
|
|
|
|
316
|
|
|
|
|
|
|
|
|
|
|
Total current Other liabilities
|
|
|
561
|
|
|
|
888
|
|
|
|
|
|
|
|
|
|
|
14
CELANESE
CORPORATION AND SUBSIDIARIES
NOTES TO
THE UNAUDITED INTERIM CONSOLIDATED
FINANCIAL
STATEMENTS (Continued)
Net
Investment Hedge
To protect the foreign currency exposure of a net investment in
a foreign operation, the Company entered into cross currency
swaps with certain financial institutions in 2004. The cross
currency swaps and the Euro-denominated portion of the senior
term loan were designated as a hedge of a net investment of a
foreign operation. Under the terms of the cross currency swap
arrangements, the Company paid
approximately 13 million in interest and
received approximately $16 million in interest on June 15
and December 15 of each year. The fair value of the net
obligation under the cross currency swaps was included in
current Other liabilities in the consolidated balance sheet as
of December 31, 2007. Upon maturity of the cross currency
swap arrangements in June 2008, the Company
owed 276 million ($426 million) and was
owed $333 million. In settlement of the obligation, the
Company paid $93 million (net of interest of
$3 million) in June 2008.
In September 2008, the Company
dedesignated 340 million of
the 400 million euro-denominated portion of the
term loan, previously designated as a hedge of a net investment
of a foreign operation. Prior to this dedesignation, the Company
entered into external derivative contracts to offset foreign
currency exposures on intercompany loans. The foreign currency
exposure resulting from dedesignation
of 340 million of the hedge of a net investment
of a foreign operation is expected to offset the foreign
currency exposure on certain intercompany loans, decreasing the
need for external derivative contracts and reducing the
Companys exposure to external counterparties. The
remaining 60 million euro-denominated portion of
the term loan continues to be designated as a hedge of a net
investment of a foreign operation.
The components of noncurrent Other liabilities are as follows:
|
|
|
|
|
|
|
|
|
|
|
As of
|
|
As of
|
|
|
September 30,
|
|
December 31,
|
|
|
2008
|
|
2007
|
|
|
(in $ millions)
|
|
Environmental
|
|
|
87
|
|
|
|
96
|
|
Insurance
|
|
|
85
|
|
|
|
78
|
|
Deferred revenue
|
|
|
65
|
|
|
|
71
|
|
Deferred proceeds (see Notes 3 and 16)
|
|
|
379
|
|
|
|
93
|
|
Asset retirement obligations
|
|
|
37
|
|
|
|
31
|
|
Derivatives
|
|
|
31
|
|
|
|
37
|
|
Other
|
|
|
109
|
|
|
|
89
|
|
|
|
|
|
|
|
|
|
|
Total noncurrent Other liabilities
|
|
|
793
|
|
|
|
495
|
|
|
|
|
|
|
|
|
|
|
15
CELANESE
CORPORATION AND SUBSIDIARIES
NOTES TO
THE UNAUDITED INTERIM CONSOLIDATED
FINANCIAL
STATEMENTS (Continued)
The components of net periodic benefit costs recognized are as
follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Pension Benefits
|
|
Postretirement Benefits
|
|
Pension Benefits
|
|
Postretirement Benefits
|
|
|
Three Months Ended September 30,
|
|
Nine Months Ended September 30,
|
|
|
2008
|
|
2007
|
|
2008
|
|
2007
|
|
2008
|
|
2007
|
|
2008
|
|
2007
|
|
|
(in $ millions)
|
|
Components of net periodic benefit costs
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Service cost
|
|
|
8
|
|
|
|
11
|
|
|
|
|
|
|
|
|
|
|
|
24
|
|
|
|
30
|
|
|
|
1
|
|
|
|
1
|
|
Interest cost
|
|
|
50
|
|
|
|
50
|
|
|
|
4
|
|
|
|
5
|
|
|
|
149
|
|
|
|
142
|
|
|
|
13
|
|
|
|
14
|
|
Expected return on plan assets
|
|
|
(56
|
)
|
|
|
(58
|
)
|
|
|
|
|
|
|
|
|
|
|
(167
|
)
|
|
|
(164
|
)
|
|
|
|
|
|
|
|
|
Recognized actuarial (gain) loss
|
|
|
1
|
|
|
|
|
|
|
|
(1
|
)
|
|
|
|
|
|
|
1
|
|
|
|
|
|
|
|
(3
|
)
|
|
|
(1
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net periodic benefit costs
|
|
|
3
|
|
|
|
3
|
|
|
|
3
|
|
|
|
5
|
|
|
|
7
|
|
|
|
8
|
|
|
|
11
|
|
|
|
14
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The Company expects to contribute $40 million to its
defined benefit pension plans in 2008. As of September 30,
2008, $33 million of contributions have been made. The
Companys estimates of its US defined benefit pension plan
contributions reflect the provisions of the Pension Funding
Equity Act of 2004 and the Pension Protection Act of 2006.
The Company expects to make benefit contributions of
$34 million under the provisions of its other
postretirement benefit plans in 2008. As of September 30,
2008, $25 million of benefit contributions have been made.
The Company participates in multiemployer defined benefit plans
in Europe covering certain employees. The Companys
contributions to the multiemployer defined benefit plans are
based on specified percentages of employee contributions and
totaled $5 million for both the nine months ended
September 30, 2008 and 2007.
As a result of the sale of the oxo products and derivatives
businesses in February 2007 (see Note 3), there was a
reduction of approximately 1,076 employees triggering a
settlement and remeasurement of the affected pension plans due
to certain changes in actuarial valuation assumptions. The
settlement and remeasurement resulted in a net increase in the
projected benefit obligation of $44 million with an offset
to Accumulated other comprehensive income (loss), net (net of
tax of $1 million) and a settlement gain of
$11 million (included in Gain (loss) on disposal of
discontinued operations) for the pension plan during the nine
months ended September 30, 2007.
In February 2008, the Companys Board of Directors
authorized the repurchase of up to $400 million of the
Companys Series A common stock. The authorization
gives management discretion in determining the conditions under
which shares may be repurchased. During the nine months ended
September 30, 2008, the Company repurchased
9,763,200 shares of its Series A common stock at an
average purchase price of $38.68 per share for a total of
$378 million pursuant to this authorization.
Purchases of treasury stock reduce the number of shares
outstanding and the repurchased shares may be used by the
Company for compensation programs utilizing the Companys
stock and other corporate purposes. The Company accounts for
treasury stock using the cost method and includes treasury stock
as a component of Shareholders equity.
Other comprehensive income (loss), net of tax, totaled
$(89) million and $24 million for the nine months
ended September 30, 2008 and 2007, respectively. These
amounts were net of tax expense of $0 and $4 million for
the nine months ended September 30, 2008 and 2007,
respectively. Other comprehensive income (loss), net of tax,
totaled $(98) million and $7 million for the three
months ended September 30, 2008 and 2007, respectively.
These amounts were net of tax expense of $0 and $3 million
for the three months ended September 30, 2008 and 2007,
respectively.
16
CELANESE
CORPORATION AND SUBSIDIARIES
NOTES TO
THE UNAUDITED INTERIM CONSOLIDATED
FINANCIAL
STATEMENTS (Continued)
|
|
10.
|
Commitments
and Contingencies
|
The Company is involved in a number of legal proceedings,
lawsuits and claims incidental to the normal conduct of
business, relating to such matters as product liability,
antitrust, past waste disposal practices and release of
chemicals into the environment. While it is impossible at this
time to determine with certainty the ultimate outcome of these
proceedings, lawsuits and claims, the Company believes, based on
the advice of legal counsel, that adequate provisions have been
made and that the ultimate outcomes will not have a material
adverse effect on the financial position of the Company;
however, the ultimate outcome of any given matter may have a
material impact on the results of operations or cash flows of
the Company in a given reporting period.
Plumbing
Actions
CNA Holdings, Inc. (CNA Holdings), a US subsidiary
of the Company, which included the US business now conducted by
the Ticona business which is included in the Advanced Engineered
Materials segment, along with Shell Oil Company
(Shell), E.I. DuPont de Nemours and Company
(DuPont) and others, has been a defendant in a
series of lawsuits, including a number of class actions,
alleging that plastics manufactured by these companies that were
utilized in the production of plumbing systems for residential
property were defective or caused such plumbing systems to fail.
Based on, among other things, the findings of outside experts
and the successful use of Ticonas acetal copolymer in
similar applications, CNA Holdings does not believe
Ticonas acetal copolymer was defective or caused the
plumbing systems to fail. In many cases CNA Holdings
potential future exposure may be limited by invocation of the
statute of limitations since CNA Holdings ceased selling the
resin for use in the plumbing systems in site-built homes during
1986 and in manufactured homes during 1990.
In November 1995, CNA Holdings, DuPont and Shell entered into
national class action settlements which called for the
replacement of plumbing systems of claimants who have had
qualifying leaks, as well as reimbursements for certain leak
damage. In connection with such settlement, the three companies
had agreed to fund these replacements and reimbursements up to
an aggregate amount of $950 million. As of
September 30, 2008, the aggregate funding is
$1,103 million, due to additional contributions and funding
commitments made primarily by other parties.
During the period between 1995 and 2001, CNA Holdings was also
named as a defendant in the following putative class actions:
|
|
|
|
|
Cox, et al. v. Hoechst Celanese Corporation, et al.,
No. 94-0047
(Chancery Ct., Obion County, Tennessee).
|
|
|
|
Couture, et al. v. Shell Oil Company, et al.,
No. 200-06-000001-985
(Quebec Superior Court, Canada).
|
|
|
|
Dilday, et al. v. Hoechst Celanese Corporation, et al.,
No. 15187 (Chancery Ct., Weakley County, Tennessee).
|
|
|
|
Furlan v. Shell Oil Company, et al.,
No. C967239 (British Columbia Supreme Court, Vancouver
Registry, Canada).
|
|
|
|
Gariepy, et al. v. Shell Oil Company, et al.,
No. 30781/99 (Ontario Court General Division, Canada).
|
|
|
|
Shelter General Insurance Co., et al. v. Shell Oil
Company, et al., No. 16809 (Chancery Ct.,
Weakley County, Tennessee).
|
|
|
|
St. Croix Ltd., et al. v. Shell Oil Company, et al.,
No. 1997/467 (Territorial Ct., St. Croix Division, the
US Virgin Islands).
|
|
|
|
Tranter v. Shell Oil Company, et al.,
No. 46565/97 (Ontario Court General Division, Canada).
|
In addition, between 1994 and 2003 CNA Holdings was named as a
defendant in approximately 20 non-class actions filed in ten
states, the US Virgin Islands and Canada that are currently
pending. In all of these actions, the
17
CELANESE
CORPORATION AND SUBSIDIARIES
NOTES TO
THE UNAUDITED INTERIM CONSOLIDATED
FINANCIAL
STATEMENTS (Continued)
plaintiffs have sought recovery for alleged damages caused by
leaking polybutylene plumbing. Damage amounts have generally not
been specified but these cases generally do not involve (either
individually or in the aggregate) a large number of homes.
As of September 30, 2008 the Company had remaining accruals
of $64 million, of which $2 million is included in
current Other liabilities in the consolidated balance sheet. As
of December 31, 2007, the Company had remaining accruals of
$65 million, of which $3 million was included in
current Other liabilities in the consolidated balance sheet.
Plumbing
Insurance Indemnifications
CAG entered into agreements with insurance companies related to
product liability settlements associated with
Celcon®
plumbing claims. These agreements, except those with insolvent
insurance companies, require the Company to indemnify
and/or
defend these insurance companies in the event that third parties
seek additional monies for matters released in these agreements.
The indemnifications in these agreements do not provide for time
limitations.
In certain of the agreements, CAG received a fixed settlement
amount. The indemnities under these agreements generally are
limited to, but in some cases are greater than, the amount
received in settlement from the insurance company. The maximum
exposure under these indemnifications is $95 million. Other
settlement agreements have no stated limits.
There are other agreements whereby the settling insurer agreed
to pay a fixed percentage of claims that relate to that
insurers policies. The Company has provided
indemnifications to the insurers for amounts paid in excess of
the settlement percentage. These indemnifications do not provide
for monetary or time limitations.
The Company has reserves associated with these product liability
claims which the Company believes are adequate.
Sorbates
Antitrust Actions
In May 2002, the European Commission informed Hoechst AG
(Hoechst) of its intent to officially investigate
the sorbates industry. In early January 2003, the European
Commission served Hoechst, Nutrinova, Inc., a US subsidiary of
Nutrinova Nutrition Specialties & Food Ingredients
GmbH and previously a wholly owned subsidiary of Hoechst
(Nutrinova), and a number of competitors of
Nutrinova with a statement of objections alleging unlawful,
anticompetitive behavior affecting the European sorbates market.
In October 2003, the European Commission ruled that Hoechst,
Chisso Corporation, Daicel Chemical Industries Ltd.
(Daicel), The Nippon Synthetic Chemical Industry Co.
Ltd. and Ueno Fine Chemicals Industry Ltd. operated a cartel in
the European sorbates market between 1979 and 1996. The European
Commission imposed a total fine of 138 million
on such companies, of which 99 million was
assessed against Hoechst and its legal successors. The case
against Nutrinova was closed. Pursuant to the Demerger Agreement
with Hoechst, CAG was assigned the obligation related to the
sorbates antitrust matter; however, Hoechst, and its legal
successors, agreed to indemnify CAG for 80% of any costs CAG
incurred relative to this matter. Accordingly, CAG recognized a
receivable from Hoechst from this indemnification. In June 2008,
the Court of First Instance of the European Communities (Fifth
Chamber) reduced the fine against Hoechst
to 74.25 million and in July 2008, Hoechst paid
the 74.25 million fine. In August 2008, the
Company paid Hoechst 17 million, including
interest of 2 million, in satisfaction of its 20%
obligation with respect to the fine.
Based on the advice of external counsel and a review of the
existing facts and circumstances relating to the sorbates
antitrust matters, including the settlement of the European
Unions investigation, as well as civil claims filed and
settled, the Company released its accruals related to the
settled sorbates antitrust matters and the indemnification
receivables resulting in a gain of $8 million, net,
included in Other (charges) gains, net, in the
18
CELANESE
CORPORATION AND SUBSIDIARIES
NOTES TO
THE UNAUDITED INTERIM CONSOLIDATED
FINANCIAL
STATEMENTS (Continued)
consolidated statements of operations. As of December 31,
2007, the Company had indemnification receivables of
$137 million included in current Other assets and accruals
of $170 million included in current Other liabilities in
the consolidated balance sheet.
In addition, in 2004 a civil antitrust action styled Freeman
Industries LLC v. Eastman Chemical Co., et. al. was
filed against Hoechst and Nutrinova, Inc. in the Law Court for
Sullivan County in Kingsport, Tennessee. The plaintiff sought
monetary damages and other relief for alleged conduct involving
the sorbates industry. The trial court dismissed the
plaintiffs claims and upon appeal the Supreme Court of
Tennessee affirmed the dismissal of the plaintiffs claims.
In December 2005, the plaintiff lost an attempt to amend its
complaint and the entire action was dismissed with prejudice by
the trial court. Plaintiffs counsel has subsequently filed
a new complaint with new class representatives in the District
Court of the District of Tennessee. The Companys motion to
strike the class allegations was granted in April 2008 and the
plaintiffs appeal of such ruling is currently pending.
Acetic
Acid Patent Infringement Matters
On May 9, 1999, Celanese International Corporation filed a
private criminal action styled Celanese International
Corporation v. China Petrochemical Development Corporation
against China Petrochemical Development Corporation
(CPDC) in the Taiwan Kaoshiung District Court
alleging that CPDC infringed Celanese International
Corporations patent covering the manufacture of acetic
acid. Celanese International Corporation also filed a
supplementary civil brief which, in view of changes in Taiwanese
patent laws, was subsequently converted to a civil action
alleging damages against CPDC based on a period of infringement
of ten years,
1991-2000,
and based on CPDCs own data which was reported to the
Taiwanese securities and exchange commission. Celanese
International Corporations patent was held valid by the
Taiwanese patent office. On August 31, 2005, the District
Court held that CPDC infringed Celanese International
Corporations acetic acid patent and awarded Celanese
International Corporation approximately $28 million (plus
interest) for the period of 1995 through 1999. In
October 2008, the High Court, on appeal, dismissed the
District Courts ruling. The Company is currently
considering whether to appeal this decision to the Taiwan
Supreme Court. On January 16, 2006, the District Court
awarded Celanese International Corporation $800,000 (plus
interest) for the year 1990. In addition, on June 29, 2007,
the District Court awarded Celanese International Corporation
$60 million (plus interest) for the period of 2000 through
2005. The awards for the periods of 1990 and 2000 through 2005
are currently under appeal by CPDC.
Domination
Agreement
The domination and profit and loss transfer agreement (the
Domination Agreement) between CAG and the Purchaser
was approved at the CAG extraordinary shareholders meeting
on July 31, 2004. The Domination Agreement became effective
on October 1, 2004 and cannot be terminated by the
Purchaser in the ordinary course of business until
September 30, 2009. Two of the Companys subsidiaries,
Celanese International Holdings Luxembourg S.à r.l.
(CIH), and Celanese US, have each agreed to provide
the Purchaser with financing to strengthen the Purchasers
ability to fulfill its obligations under, or in connection with,
the Domination Agreement and to ensure that the Purchaser will
perform all of its obligations under, or in connection with, the
Domination Agreement when such obligations become due,
including, without limitation, the obligation to compensate CAG
for any statutory annual loss incurred by CAG during the term of
the Domination Agreement. If CIH
and/or
Celanese US are obligated to make payments under such guarantees
or other security to the Purchaser, the Company may not have
sufficient funds for payments on its indebtedness when due. The
Company has not had to compensate CAG for an annual loss for any
period during which the Domination Agreement has been in effect.
Shareholder
Litigation
The amounts of the fair cash compensation and of the guaranteed
annual payment offered under the Domination Agreement may be
increased in special award proceedings initiated by minority
shareholders, which
19
CELANESE
CORPORATION AND SUBSIDIARIES
NOTES TO
THE UNAUDITED INTERIM CONSOLIDATED
FINANCIAL
STATEMENTS (Continued)
may further reduce the funds the Purchaser can otherwise make
available to the Company. As of March 30, 2005, several
minority shareholders of CAG had initiated special award
proceedings seeking the courts review of the amounts of
the fair cash compensation and of the guaranteed annual payment
offered under the Domination Agreement. As a result of these
proceedings, the amount of the fair cash consideration and the
guaranteed annual payment offered under the Domination Agreement
could be increased by the court so that all minority
shareholders, including those who have already tendered their
shares into the mandatory offer and have received the fair cash
compensation could claim the respective higher amounts. The
court dismissed all of these proceedings in March 2005 on the
grounds of inadmissibility. Thirty-three plaintiffs appealed the
dismissal, and in January 2006, twenty-three of these appeals
were granted by the court. They were remanded back to the court
of first instance, where the valuation will be further reviewed.
On December 12, 2006, the court of first instance appointed
an expert to help determine the value of CAG. In the first
quarter of 2007, certain minority shareholders that
received 66.99 per share as fair cash compensation
also filed award proceedings challenging the amount they
received as fair cash compensation.
As a result of the special proceedings discussed above, amounts
paid as fair cash compensation to certain minority shareholders
of CAG could be increased by the court such that minority
shareholders could be awarded amounts in excess of the fair cash
compensation they have previously received.
The Company received applications for the commencement of award
proceedings filed by 79 shareholders against the Purchaser
with the Frankfurt District Court requesting the court to set a
higher amount for the Squeeze-Out compensation. The motions are
based on various alleged shortcomings and mistakes in the
valuation of CAG done for purposes of the Squeeze-Out. On
May 11, 2007, the court of first instance appointed a
common representative for those shareholders that have not filed
an application on their own.
The shareholders resolution approving the Squeeze-Out
passed at the shareholders meeting on May 30, 2006
was challenged in June 2006 by seventeen actions seeking to set
aside such resolution. In addition, a null and void action was
served upon CAG in November 2006. The Squeeze-Out required
registration in the commercial register and such registration
was not possible while the lawsuits were pending. Therefore, CAG
initiated fast track release proceedings asking the court to
find that the lawsuits did not prevent registration of the
Squeeze-Out. The court of first instance granted the motion
regarding the actions to set aside the shareholders
resolution in a ruling dated October 10, 2006 that was
appealed by plaintiff shareholders. In a ruling dated
November 30, 2006, the court of first instance also granted
the motion with respect to the null and void action.
On December 22, 2006, the Purchaser and CAG signed a
settlement agreement with the plaintiff shareholders challenging
the shareholders resolution approving the Squeeze-Out
(Settlement Agreement I). Pursuant to Settlement
Agreement I, the plaintiffs agreed to withdraw their
actions and to drop their complaints in exchange for the
Purchaser agreeing to pay the guaranteed annual payment for the
fiscal year ended on September 30, 2006 to those minority
shareholders who had not yet requested early payment of such
dividend and to pay a pro rata share of the guaranteed annual
payment for the first five months of the fiscal year ending on
September 30, 2007 to all minority shareholders. The
Purchaser further agreed to make a donation in the amount
of 0.5 million to a charity, to introduce the
prospectus governing the January 20, 2005 listing on the
NYSE of the shares of the Company, upon request by plaintiffs,
into the award proceedings regarding the cash compensation and
the guaranteed annual payment under the Domination Agreement and
to accord the squeezed-out minority shareholders preferential
treatment if, within three years after effectiveness of the
Squeeze-Out, the shares of CAG were to be listed on a stock
exchange again. As a result of the effective registration of the
Squeeze-Out in the commercial register in Germany in December
2006, the Company acquired the remaining 2% of CAG in January
2007.
Polyester
Staple Antitrust Litigation
CNA Holdings, the successor in interest to Hoechst Celanese
Corporation (HCC), Celanese Americas Corporation and
CAG (collectively, the Celanese Entities) and
Hoechst, the former parent of HCC, were named
20
CELANESE
CORPORATION AND SUBSIDIARIES
NOTES TO
THE UNAUDITED INTERIM CONSOLIDATED
FINANCIAL
STATEMENTS (Continued)
as defendants in two actions (involving 25 individual
participants) filed in September 2006 by US purchasers of
polyester staple fibers manufactured and sold by HCC. The
actions allege that the defendants participated in a conspiracy
to fix prices, rig bids and allocate customers of polyester
staple sold in the United States. These actions were
consolidated in a proceeding by a Multi-District Litigation
Panel in the United States District Court for the Western
District of North Carolina styled In re Polyester Staple
Antitrust Litigation, MDL 1516. On June 12, 2008 the
court dismissed these actions against all Celanese Entities in
consideration of a payment by the Company of $107 million.
This proceeding related to sales by the polyester staple fibers
business which Hoechst AG sold to KoSa, Inc. in 1998.
Accordingly, the impact of this settlement is reflected within
discontinued operations on the Companys 2008 unaudited
interim consolidated statements of operations. The Company also
previously entered into tolling arrangements with four other
alleged US purchasers of polyester staple fibers manufactured
and sold by the Celanese Entities. These purchasers were not
included in the settlement.
In 1998, HCC sold its polyester staple business as part of the
sale of its Film & Fibers Division to KoSa B.V.,
f/k/a Arteva
B.V. and a subsidiary of Koch Industries, Inc.
(KoSa). In March 2001 the US Department of Justice
(DOJ) commenced an investigation of possible price
fixing regarding the sales of polyester staple fibers in the US
subsequent to the period the Celanese Entities were engaged in
the polyester staple fiber business. The Celanese Entities were
never named in these DOJ actions. As a result of the DOJ action,
during August of 2002, Arteva Specialties, S.a.r.l., a
subsidiary of KoSa, (Arteva Specialties) pled guilty
to criminal violation of the Sherman Act related to
anti-competitive conduct occurring after the 1998 sale of the
polyester staple fiber business and paid a fine of
$29 million. In a complaint pending against the Celanese
Entities and Hoechst in the United States District Court for the
Southern District of New York, Koch Industries, Inc., KoSa,
Arteva Specialties and Arteva Services S.a.r.l. seek damages up
to $371 million which includes indemnification for all
damages related to the defendants alleged participation
in, and failure to disclose, the alleged conspiracy. The Company
is actively defending this matter.
Guarantees
The Company has agreed to guarantee or indemnify third parties
for environmental and other liabilities pursuant to a variety of
agreements, including asset and business divestiture agreements,
leases, settlement agreements and various agreements with
affiliated companies. Although many of these obligations contain
monetary
and/or time
limitations, others do not provide such limitations.
As indemnification obligations often depend on the occurrence of
unpredictable future events, the future costs associated with
them cannot be determined at this time.
The Company has accrued for all probable and reasonably
estimable losses associated with all known matters or claims
that have been brought to its attention. These known obligations
include the following:
Demerger
Obligations
The Company has obligations to indemnify Hoechst, and its legal
successors, for various liabilities under the Demerger
Agreement, including for environmental liabilities associated
with contamination arising under 19 divestiture agreements
entered into by Hoechst prior to the demerger.
The Companys obligation to indemnify Hoechst, and its
legal successors, is subject to the following thresholds:
|
|
|
|
|
The Company will indemnify Hoechst, and its legal successors,
against those liabilities up to 250 million;
|
|
|
|
Hoechst, and its legal successors, will bear those liabilities
exceeding 250 million, however the Company will
reimburse Hoechst, and its legal successors, for one-third of
those liabilities for amounts that exceed 750 million
in the aggregate.
|
21
CELANESE
CORPORATION AND SUBSIDIARIES
NOTES TO
THE UNAUDITED INTERIM CONSOLIDATED
FINANCIAL
STATEMENTS (Continued)
The aggregate maximum amount of environmental indemnifications
under the remaining divestiture agreements that provide for
monetary limits is approximately 750 million.
Three of the divestiture agreements do not provide for monetary
limits.
Based on the estimate of the probability of loss under this
indemnification, the Company had reserves of $28 million
and $27 million as of September 30, 2008 and
December 31, 2007, respectively, for this contingency.
Where the Company is unable to reasonably determine the
probability of loss or estimate such loss under an
indemnification, the Company has not recognized any related
liabilities.
The Company has also undertaken in the Demerger Agreement to
indemnify Hoechst and its legal successors for liabilities that
Hoechst is required to discharge, including tax liabilities,
which are associated with businesses that were included in the
demerger but were not demerged due to legal restrictions on the
transfers of such items. These indemnities do not provide for
any monetary or time limitations. The Company has not provided
for any reserves associated with this indemnification. The
Company has not made any payments to Hoechst or its legal
successors during the nine months ended September 30, 2008
and 2007, respectively, in connection with this indemnification.
Divestiture
Obligations
The Company and its predecessor companies agreed to indemnify
third-party purchasers of former businesses and assets for
various pre-closing conditions, as well as for breaches of
representations, warranties and covenants. Such liabilities also
include environmental liability, product liability, antitrust
and other liabilities. These indemnifications and guarantees
represent standard contractual terms associated with typical
divestiture agreements and, other than environmental
liabilities, the Company does not believe that they expose the
Company to any significant risk.
The Company has divested numerous businesses, investments and
facilities through agreements containing indemnifications or
guarantees to the purchasers. Many of the obligations contain
monetary
and/or time
limitations, ranging from one year to thirty years. The
aggregate amount of guarantees provided for under these
agreements is approximately $2.5 billion as of
September 30, 2008. Other agreements do not provide for any
monetary or time limitations.
Based on historical claims experience and its knowledge of the
sites and businesses involved, the Company believes that it is
adequately reserved for these matters. As of September 30,
2008 and December 31, 2007, the Company has reserves in the
aggregate of $36 million and $27 million,
respectively, for these matters.
Other
Obligations
The Company is secondarily liable under a lease agreement that
the Company assigned to a third party. The lease expires on
April 30, 2012. The lease liability for the period from
October 1, 2008 to April 30, 2012 is estimated to be
approximately $28 million.
Asbestos
Claims
As of September 30, 2008, Celanese Ltd. and/or CNA
Holdings, Inc., both US subsidiaries of the Company, are
defendants in approximately 572 asbestos cases. During the nine
months ended September 30, 2008, 57 new cases were filed
against the Company, 114 cases were resolved, and 4 cases were
added and 1 removed after further analysis by outside counsel.
Because many of these cases involve numerous plaintiffs, the
Company is subject to claims significantly in excess of the
number of actual cases. The Company has reserves for defense
costs related to claims arising from these matters. The Company
believes that there is no significant exposure related to these
matters.
22
CELANESE
CORPORATION AND SUBSIDIARIES
NOTES TO
THE UNAUDITED INTERIM CONSOLIDATED
FINANCIAL
STATEMENTS (Continued)
|
|
11.
|
Fair
Value Measurements
|
On January 1, 2008, the Company adopted the provisions of
SFAS No. 157, Fair Value Measurements
(SFAS No. 157) for financial assets
and liabilities. SFAS No. 157 became effective for
financial assets and liabilities on January 1, 2008. On
January 1, 2009, the Company will apply the provisions of
SFAS No. 157 for non-recurring fair value measurements
of non-financial assets and liabilities, such as goodwill,
indefinite-lived intangible assets, property, plant and
equipment and asset retirement obligations.
SFAS No. 157 defines fair value, thereby eliminating
inconsistencies in guidance found in various prior accounting
pronouncements, and increases disclosures surrounding fair value
calculations.
SFAS No. 157 establishes a three-tiered fair value
hierarchy that prioritizes inputs to valuation techniques used
in fair value calculations. The three levels of inputs are
defined as follows:
|
|
|
|
Level 1
|
unadjusted quoted prices for identical assets or liabilities in
active markets accessible by the Company
|
Level 2 inputs that are observable in the
marketplace other than those inputs classified as Level 1
Level 3 inputs that are unobservable in the
marketplace and significant to the valuation
SFAS No. 157 requires the Company to maximize the use
of observable inputs and minimize the use of unobservable
inputs. If a financial instrument uses inputs that fall in
different levels of the hierarchy, the instrument will be
categorized based upon the lowest level of input that is
significant to the fair value calculation.
The Companys financial assets and liabilities are measured
at fair value on a recurring basis and include securities
available for sale and derivative financial instruments.
Securities available for sale include US government and
corporate bonds, mortgage-backed securities and equity
securities. Derivative financial instruments include interest
rate swaps and foreign currency forwards and swaps.
Marketable Securities. Where possible, the
Company utilizes quoted prices in active markets to measure debt
and equity securities; such items are classified as Level 1
in the hierarchy and include equity securities and US government
bonds. When quoted market prices for identical assets are
unavailable, varying valuation techniques are used. Common
inputs in valuing these assets include, among others, benchmark
yields, issuer spreads, forward mortgage-backed securities trade
prices and recently reported trades. Such assets are classified
as Level 2 in the hierarchy and typically include
mortgage-backed securities, corporate bonds and other US
government securities.
Derivatives. Derivative financial instruments
are valued in the market using discounted cash flow techniques.
These techniques incorporate Level 1 and Level 2
inputs such as interest rates and foreign currency exchange
rates. These market inputs are utilized in the discounted cash
flow calculation considering the instruments term,
notional amount, discount rate and credit risk. Significant
inputs to the derivative valuation for interest rate swaps and
foreign currency forwards and swaps are observable in the active
markets and are classified as Level 2 in the hierarchy.
23
CELANESE
CORPORATION AND SUBSIDIARIES
NOTES TO
THE UNAUDITED INTERIM CONSOLIDATED
FINANCIAL
STATEMENTS (Continued)
The following fair value hierarchy table presents information
about the Companys assets and liabilities measured at fair
value on a recurring basis:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Fair Value Measurement as of
|
|
|
|
|
September 30, 2008 Using
|
|
|
|
|
Quoted Prices in
|
|
|
|
|
|
|
Active Markets for
|
|
Significant Other
|
|
|
|
|
Identical Assets
|
|
Observable Inputs
|
|
As of
|
|
|
(Level 1)
|
|
(Level 2)
|
|
September 30, 2008
|
|
|
(in $ millions)
|
|
Assets
|
|
|
|
|
|
|
|
|
|
|
|
|
Marketable securities
|
|
|
90
|
|
|
|
129
|
|
|
|
219
|
|
Current derivatives (included in Receivables: Other)
|
|
|
|
|
|
|
67
|
|
|
|
67
|
|
Noncurrent derivatives (included in noncurrent Other assets)
|
|
|
|
|
|
|
1
|
|
|
|
1
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total assets
|
|
|
90
|
|
|
|
197
|
|
|
|
287
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Liabilities
|
|
|
|
|
|
|
|
|
|
|
|
|
Current derivatives (included in current Other liabilities)
|
|
|
|
|
|
|
28
|
|
|
|
28
|
|
Noncurrent derivatives (included in noncurrent Other liabilities)
|
|
|
|
|
|
|
31
|
|
|
|
31
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total liabilities
|
|
|
|
|
|
|
59
|
|
|
|
59
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
12.
|
Other
(Charges) Gains, Net
|
The components of Other (charges) gains, net are as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended
|
|
Nine Months Ended
|
|
|
September 30,
|
|
September 30,
|
|
|
2008
|
|
2007
|
|
2008
|
|
2007
|
|
|
|
|
(in $ millions)
|
|
|
|
Employee termination benefits
|
|
|
(8
|
)
|
|
|
(2
|
)
|
|
|
(19
|
)
|
|
|
(27
|
)
|
Plant/office closures
|
|
|
|
|
|
|
(4
|
)
|
|
|
(7
|
)
|
|
|
(4
|
)
|
Plumbing actions insurance recoveries (see
Note 10 Plumbing Insurance Indemnifications)
|
|
|
|
|
|
|
2
|
|
|
|
|
|
|
|
2
|
|
Ticona Kelsterbach plant relocation (see Note 16)
|
|
|
(3
|
)
|
|
|
(1
|
)
|
|
|
(8
|
)
|
|
|
(4
|
)
|
Deferred compensation triggered by Exit Event
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(74
|
)
|
Asset impairments (see Note 3 Asset Sales)
|
|
|
(21
|
)
|
|
|
(6
|
)
|
|
|
(21
|
)
|
|
|
(9
|
)
|
Clear Lake, Texas insurance recoveries (see Note 18)
|
|
|
23
|
|
|
|
|
|
|
|
23
|
|
|
|
|
|
Sorbates antitrust actions (see Note 10
Sorbates Antitrust Actions)
|
|
|
8
|
|
|
|
|
|
|
|
8
|
|
|
|
|
|
Other
|
|
|
|
|
|
|
(1
|
)
|
|
|
|
|
|
|
(2
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total Other (charges) gains, net
|
|
|
(1
|
)
|
|
|
(12
|
)
|
|
|
(24
|
)
|
|
|
(118
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Employee termination benefits relate primarily to the
Companys continued strategy to simplify and optimize its
business portfolio.
24
CELANESE
CORPORATION AND SUBSIDIARIES
NOTES TO
THE UNAUDITED INTERIM CONSOLIDATED
FINANCIAL
STATEMENTS (Continued)
In May 2007, the Original Shareholders sold their remaining
equity interest in the Company (Exit Event as
defined in the deferred compensation plan document) triggering a
clause in the 2004 deferred compensation program that resulted
in the vesting of certain awards. As a result, the Company
expensed $74 million representing deferred compensation
plan payments for the respective participants 2005 and
2006 contingent benefits.
Additions to the restructuring reserves are employee termination
benefits recorded as Other (charges) gains, net. The changes in
the restructuring reserves are as follows:
|
|
|
|
|
|
|
Nine Months Ended
|
|
|
September 30, 2008
|
|
|
(in $ millions)
|
|
Restructuring reserves as of December 31, 2007
|
|
|
45
|
|
Additions
|
|
|
19
|
|
Cash payments
|
|
|
(26
|
)
|
Exchange rate changes
|
|
|
(2
|
)
|
|
|
|
|
|
Restructuring reserves as of September 30, 2008
|
|
|
36
|
|
|
|
|
|
|
Included in the restructuring reserves are $0 and
$5 million as of September 30, 2008 and
December 31, 2007, respectively, of reserves recorded in
noncurrent Other liabilities in the consolidated balance sheets.
The Companys effective income tax rate for the three
months ended September 30, 2008 was (8)% compared to 1% for
the three months ended September 30, 2007. The effective
income tax rate decreased for the three months ended
September 30, 2008 primarily due to the Companys
change in estimate for the US tax effect on foreign earnings and
dividends. The Companys effective income tax rate for the
nine months ended September 30, 2008 was 17% compared to 4%
for the nine months ended September 30, 2007. The effective
income tax rate increased for the nine months ended
September 30, 2008 primarily due to income tax benefits
recognized in 2007 related to German income tax reform and US
debt refinancing, which were partially offset by the US income
tax effect resulting from the maturity of cross currency swap
arrangements in June 2008 (see Note 7) and the lower
US tax effect on foreign earnings and dividends. The overall
effective income tax rate is less than the US statutory federal
and state rates primarily due to income being taxed at lower
rates in various foreign jurisdictions.
FASB Interpretation No. 48, Accounting for Uncertainty
in Income Taxes an interpretation of FASB Statement
No. 109, (FIN 48) liabilities for
unrecognized tax benefits and related interest and penalties are
recorded in Uncertain tax positions in the consolidated balance
sheets. For the nine months ended September 30, 2008, the
total unrecognized tax benefits recorded under FIN 48
increased by $18 million primarily due to additional
interest and increases in unrecognized tax benefits in foreign
jurisdictions partially offset by currency translation
adjustments. Of the $18 million increase, $8 million
relates to current year increases, $18 million relates to
pre-acquisition
increases and $(8) million relates to currency translation
adjustments.
25
CELANESE
CORPORATION AND SUBSIDIARIES
NOTES TO
THE UNAUDITED INTERIM CONSOLIDATED
FINANCIAL
STATEMENTS (Continued)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Advanced
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Engineered
|
|
|
Consumer
|
|
|
Industrial
|
|
|
Acetyl
|
|
|
Other
|
|
|
|
|
|
|
|
|
|
Materials
|
|
|
Specialties
|
|
|
Specialties
|
|
|
Intermediates
|
|
|
Activities
|
|
|
Eliminations
|
|
|
Consolidated
|
|
|
|
(in $ millions)
|
|
|
For the three months ended September 30, 2008
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net sales
|
|
|
272
|
|
|
|
295
|
|
|
|
378
|
|
|
|
1,056
|
(1)
|
|
|
|
|
|
|
(178
|
)
|
|
|
1,823
|
|
Earnings (loss) from continuing operations before tax and
minority interests
|
|
|
25
|
|
|
|
43
|
|
|
|
18
|
|
|
|
133
|
|
|
|
(67
|
)
|
|
|
|
|
|
|
152
|
|
Depreciation and amortization
|
|
|
19
|
|
|
|
13
|
|
|
|
15
|
|
|
|
36
|
|
|
|
2
|
|
|
|
|
|
|
|
85
|
|
Capital
expenditures(3)
|
|
|
16
|
|
|
|
15
|
|
|
|
18
|
|
|
|
21
|
|
|
|
3
|
|
|
|
|
|
|
|
73
|
|
For the three months ended September 30, 2007
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net sales
|
|
|
258
|
|
|
|
282
|
|
|
|
314
|
|
|
|
864
|
(1)
|
|
|
1
|
|
|
|
(146
|
)
|
|
|
1,573
|
|
Earnings (loss) from continuing operations before tax and
minority interests
|
|
|
54
|
|
|
|
35
|
|
|
|
(9
|
)
|
|
|
145
|
|
|
|
(94
|
)
|
|
|
|
|
|
|
131
|
|
Depreciation and amortization
|
|
|
17
|
|
|
|
15
|
|
|
|
13
|
|
|
|
31
|
|
|
|
1
|
|
|
|
|
|
|
|
77
|
|
Capital expenditures
|
|
|
16
|
|
|
|
11
|
|
|
|
18
|
|
|
|
55
|
|
|
|
1
|
|
|
|
|
|
|
|
101
|
|
For the nine months ended September 30, 2008
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net sales
|
|
|
866
|
|
|
|
869
|
|
|
|
1,129
|
|
|
|
3,219
|
(2)
|
|
|
1
|
|
|
|
(547
|
)
|
|
|
5,537
|
|
Earnings (loss) from continuing operations before tax and
minority interests
|
|
|
112
|
|
|
|
187
|
|
|
|
55
|
|
|
|
520
|
|
|
|
(257
|
)
|
|
|
|
|
|
|
617
|
|
Depreciation and amortization
|
|
|
58
|
|
|
|
40
|
|
|
|
43
|
|
|
|
102
|
|
|
|
7
|
|
|
|
|
|
|
|
250
|
|
Capital
expenditures(3)
|
|
|
43
|
|
|
|
35
|
|
|
|
47
|
|
|
|
62
|
|
|
|
7
|
|
|
|
|
|
|
|
194
|
|
Total assets as of September 30, 2008
|
|
|
1,916
|
|
|
|
1,058
|
|
|
|
1,014
|
|
|
|
2,764
|
|
|
|
1,220
|
|
|
|
|
|
|
|
7,972
|
|
For the nine months ended September 30, 2007
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net sales
|
|
|
777
|
|
|
|
832
|
|
|
|
1,015
|
|
|
|
2,532
|
(2)
|
|
|
2
|
|
|
|
(474
|
)
|
|
|
4,684
|
|
Earnings (loss) from continuing operations before tax and
minority interests
|
|
|
152
|
|
|
|
164
|
|
|
|
2
|
|
|
|
391
|
|
|
|
(575
|
)
|
|
|
|
|
|
|
134
|
|
Depreciation and amortization
|
|
|
51
|
|
|
|
39
|
|
|
|
43
|
|
|
|
81
|
|
|
|
4
|
|
|
|
|
|
|
|
218
|
|
Capital expenditures
|
|
|
31
|
|
|
|
25
|
|
|
|
46
|
|
|
|
112
|
|
|
|
3
|
|
|
|
|
|
|
|
217
|
|
Total assets as of December 31, 2007
|
|
|
1,751
|
|
|
|
1,157
|
|
|
|
995
|
|
|
|
2,530
|
|
|
|
1,625
|
|
|
|
|
|
|
|
8,058
|
|
|
|
|
(1) |
|
Includes $178 million and $146 million of
inter-segment sales eliminated in consolidation for the three
months ended September 30, 2008 and 2007, respectively. |
|
(2) |
|
Includes $547 million and $474 million of
inter-segment sales eliminated in consolidation for the nine
months ended September 30, 2008 and 2007, respectively. |
|
(3) |
|
Includes decrease of $3 million and $18 million in
accrued capital expenditures since December 31, 2007 for
the three and nine months ended September 30, 2008,
respectively. |
26
CELANESE
CORPORATION AND SUBSIDIARIES
NOTES TO
THE UNAUDITED INTERIM CONSOLIDATED
FINANCIAL
STATEMENTS (Continued)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended September 30,
|
|
|
|
2008
|
|
|
2007
|
|
|
|
Basic
|
|
|
Diluted
|
|
|
Basic
|
|
|
Diluted
|
|
|
|
(in $ millions, except for share and per share data)
|
|
|
Earnings (loss) from continuing operations
|
|
|
164
|
|
|
|
164
|
|
|
|
130
|
|
|
|
130
|
|
Earnings (loss) from discontinued operations
|
|
|
(6
|
)
|
|
|
(6
|
)
|
|
|
(2
|
)
|
|
|
(2
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net earnings (loss)
|
|
|
158
|
|
|
|
158
|
|
|
|
128
|
|
|
|
128
|
|
Less: cumulative preferred stock dividends
|
|
|
(3
|
)
|
|
|
|
|
|
|
(2
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Earnings (loss) available to common shareholders
|
|
|
155
|
|
|
|
158
|
|
|
|
126
|
|
|
|
128
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted-average shares basic
|
|
|
147,063,241
|
|
|
|
147,063,241
|
|
|
|
150,154,309
|
|
|
|
150,154,309
|
|
Dilutive stock options
|
|
|
|
|
|
|
3,367,888
|
|
|
|
|
|
|
|
4,790,700
|
|
Dilutive restricted stock
|
|
|
|
|
|
|
418,300
|
|
|
|
|
|
|
|
421,740
|
|
Assumed conversion of preferred stock
|
|
|
|
|
|
|
12,062,260
|
|
|
|
|
|
|
|
12,043,298
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted-average shares diluted
|
|
|
147,063,241
|
|
|
|
162,911,689
|
|
|
|
150,154,309
|
|
|
|
167,410,047
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Per share:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Earnings (loss) from continuing operations
|
|
|
1.09
|
|
|
|
1.01
|
|
|
|
0.85
|
|
|
|
0.77
|
|
Earnings (loss) from discontinued operations
|
|
|
(0.04
|
)
|
|
|
(0.04
|
)
|
|
|
(0.01
|
)
|
|
|
(0.01
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net earnings (loss)
|
|
|
1.05
|
|
|
|
0.97
|
|
|
|
0.84
|
|
|
|
0.76
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Nine Months Ended September 30,
|
|
|
|
2008
|
|
|
2007
|
|
|
|
Basic
|
|
|
Diluted
|
|
|
Basic
|
|
|
Diluted
|
|
|
|
(in $ millions, except for share and per share data)
|
|
|
Earnings (loss) from continuing operations
|
|
|
512
|
|
|
|
512
|
|
|
|
128
|
|
|
|
128
|
|
Earnings (loss) from discontinued operations
|
|
|
(75
|
)
|
|
|
(75
|
)
|
|
|
84
|
|
|
|
84
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net earnings (loss)
|
|
|
437
|
|
|
|
437
|
|
|
|
212
|
|
|
|
212
|
|
Less: cumulative preferred stock dividends
|
|
|
(8
|
)
|
|
|
|
|
|
|
(7
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Earnings (loss) available to common shareholders
|
|
|
429
|
|
|
|
437
|
|
|
|
205
|
|
|
|
212
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted-average shares basic
|
|
|
149,976,915
|
|
|
|
149,976,915
|
|
|
|
155,423,930
|
|
|
|
155,423,930
|
|
Dilutive stock options
|
|
|
|
|
|
|
3,412,357
|
|
|
|
|
|
|
|
4,357,815
|
|
Dilutive restricted stock
|
|
|
|
|
|
|
556,478
|
|
|
|
|
|
|
|
290,923
|
|
Assumed conversion of preferred stock
|
|
|
|
|
|
|
12,062,260
|
|
|
|
|
|
|
|
12,043,298
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted-average shares diluted
|
|
|
149,976,915
|
|
|
|
166,008,010
|
|
|
|
155,423,930
|
|
|
|
172,115,966
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Per share:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Earnings (loss) from continuing operations
|
|
|
3.36
|
|
|
|
3.08
|
|
|
|
0.78
|
|
|
|
0.74
|
|
Earnings (loss) from discontinued operations
|
|
|
(0.50
|
)
|
|
|
(0.45
|
)
|
|
|
0.54
|
|
|
|
0.49
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net earnings (loss)
|
|
|
2.86
|
|
|
|
2.63
|
|
|
|
1.32
|
|
|
|
1.23
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
27
CELANESE
CORPORATION AND SUBSIDIARIES
NOTES TO
THE UNAUDITED INTERIM CONSOLIDATED
FINANCIAL
STATEMENTS (Continued)
The following securities were not included in the computation of
diluted net earnings per share as their effect would have been
antidilutive:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months
|
|
|
Nine Months
|
|
|
|
Ended September 30,
|
|
|
Ended September 30,
|
|
|
|
2008
|
|
|
2007
|
|
|
2008
|
|
|
2007
|
|
|
Stock options
|
|
|
773,750
|
|
|
|
408,333
|
|
|
|
711,875
|
|
|
|
247,899
|
|
Restricted stock units
|
|
|
66,250
|
|
|
|
|
|
|
|
22,083
|
|
|
|
|
|
Convertible preferred stock
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
|
840,000
|
|
|
|
408,333
|
|
|
|
733,958
|
|
|
|
247,899
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
16.
|
Ticona
Kelsterbach Plant Relocation
|
In 2007, the Company finalized a settlement agreement with the
Frankfurt, Germany, Airport (Fraport) to relocate
the Kelsterbach, Germany Ticona business, resolving several
years of legal disputes related to the planned Frankfurt airport
expansion. As a result of the settlement, the Company will
transition Ticonas operations from Kelsterbach to the
Hoechst Industrial Park in the Rhine Main area in Germany by
mid-2011. Over a five-year period, Fraport will pay Ticona a
total of 670 million to offset the costs
associated with the transition of the business from its current
location and the closure of the Kelsterbach plant. In June 2008,
the Company received 200 million
($311 million) from Fraport under this agreement. Amounts
received from Fraport are accounted for as deferred proceeds and
are included in noncurrent Other liabilities in the consolidated
balance sheets. Additionally, in June 2008, the Company
received 38 million ($59 million) in
value-added tax from Fraport of which 38 million
($56 million) was remitted to the tax authorities in August
2008.
Below is a summary of the financial statement impact associated
with the Ticona Kelsterbach plant relocation:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Nine Months Ended
|
|
|
Total From
|
|
|
|
September 30,
|
|
|
Inception Through
|
|
|
|
2008
|
|
|
2007
|
|
|
September 30, 2008
|
|
|
|
(in $ millions)
|
|
|
Proceeds received from Fraport
|
|
|
311
|
|
|
|
|
|
|
|
337
|
|
Costs expensed
|
|
|
8
|
|
|
|
4
|
|
|
|
13
|
|
Costs capitalized
|
|
|
130
|
(1)
|
|
|
13
|
|
|
|
171
|
|
|
|
|
(1) |
|
Includes increase in accrued capital expenditures of
$8 million since December 31, 2007. |
General The Company is subject to
environmental laws and regulations worldwide which impose
limitations on the discharge of pollutants into the air and
water and establish standards for the treatment, storage and
disposal of solid and hazardous wastes. The Company believes
that it is in substantial compliance with all applicable
environmental laws and regulations. The Company is also subject
to retained environmental obligations specified in various
contractual agreements arising from divestiture of certain
businesses by the Company or one of its predecessor companies.
The Companys environmental reserves for remediation
matters were $104 million and $115 million as of
September 30, 2008 and December 31, 2007, respectively.
Remediation Due to its industrial history and
through retained contractual and legal obligations, the Company
has the obligation to remediate specific areas on its own sites
as well as on divested, orphan or US Superfund sites (as defined
below). In addition, as part of the demerger agreement between
the Company and Hoechst, a specified portion of the
responsibility for environmental liabilities from a number of
Hoechst divestitures was transferred to the Company. The Company
provides for such obligations when the event of loss is probable
and
28
CELANESE
CORPORATION AND SUBSIDIARIES
NOTES TO
THE UNAUDITED INTERIM CONSOLIDATED
FINANCIAL
STATEMENTS (Continued)
reasonably estimable. The Company believes that environmental
remediation costs will not have a material adverse effect on the
financial position of the Company, but may have a material
adverse effect on the results of operations or cash flows in any
given accounting period.
US Superfund Sites In the US, the Company may
be subject to substantial claims brought by US federal or state
regulatory agencies or private individuals pursuant to statutory
authority or common law. In particular, the Company has a
potential liability under the US Federal Comprehensive
Environmental Response, Compensation and Liability Act of 1980,
as amended, and related state laws (collectively referred to as
Superfund) for investigation and cleanup costs at
approximately 50 sites. At most of these sites, numerous
companies, including certain companies comprising the Company,
or one of its predecessor companies, have been notified that the
Environmental Protection Agency, state governing bodies or
private individuals consider such companies to be potentially
responsible parties (PRP) under Superfund or related
laws. The proceedings relating to these sites are in various
stages. The cleanup process has not been completed at most sites
and the status of the insurance coverage for most of these
proceedings is uncertain. Consequently, the Company cannot
determine accurately its ultimate liability for investigation or
cleanup costs at these sites.
As events progress at each site for which it has been named a
PRP, the Company accrues, as appropriate, a liability for site
cleanup. Such liabilities include all costs that are probable
and can be reasonably estimated. In establishing these
liabilities, the Company considers its shipment of waste to a
site, its percentage of total waste shipped to the site, the
types of wastes involved, the conclusions of any studies, the
magnitude of any remedial actions that may be necessary and the
number and viability of other PRPs. Often the Company joins with
other PRPs to sign joint defense agreements that settle, among
PRPs, each partys percentage allocation of costs at the
site. Although the ultimate liability may differ from the
estimate, the Company routinely reviews the liabilities and
revises the estimate, as appropriate, based on the most current
information available. The Company had provisions totaling
$11 million and $13 million, respectively, as of
September 30, 2008 and December 31, 2007 for US
Superfund sites.
Additional information relating to environmental remediation
activity is contained in the footnotes to the Companys
consolidated financial statements included in the 2007
Form 10-K.
|
|
18.
|
Clear
Lake, Texas Outage
|
In May 2007, the Company announced that it had an unplanned
outage at its Clear Lake, Texas acetic acid facility. At that
time, the Company originally expected the outage to last until
the end of May. Upon restart of the facility, additional
operating issues were identified which necessitated an extension
of the outage for further, more extensive repairs. In July 2007,
the Company announced that the further repairs were unsuccessful
on restart of the unit. All repairs were completed in early
August 2007 and normal production capacity resumed. During the
three months ended September 30, 2008 and the year ended
December 31, 2007, the Company recorded approximately
$23 million and $40 million, respectively, of
insurance recoveries from its reinsurers in partial satisfaction
of claims that the Company made based on losses resulting from
the outage. These insurances recoveries are included in Other
(charges) gains, net, in the consolidated statements of
operations.
On October 3, 2008, the Company declared a cash dividend on
its 4.25% convertible perpetual preferred stock amounting to
approximately $2 million and a cash dividend of $0.04 per
share on its Series A common stock amounting to
approximately $6 million. Both cash dividends are for the
period August 1, 2008 to October 31, 2008 and will be
paid on November 1, 2008 to holders of record as of
October 15, 2008.
29
|
|
Item 2.
|
Managements
Discussion and Analysis of Financial Condition and Results of
Operations
|
In this Quarterly Report on
Form 10-Q,
the term Celanese refers to Celanese Corporation, a
Delaware corporation, and not its subsidiaries. The terms the
Company, we, our and
us, refer to Celanese and its subsidiaries on a
consolidated basis. The term Celanese US refers to
our subsidiary, Celanese US Holdings LLC, a Delaware limited
liability company, formally known as BCP Crystal US Holdings
Corp., a Delaware corporation, and not its subsidiaries. The
term Purchaser refers to our subsidiary, Celanese
Europe Holding GmbH & Co. KG, formerly known as BCP
Crystal Acquisition GmbH & Co. KG, a German limited
partnership, and not its subsidiaries, except where otherwise
indicated.
Managements Discussion and Analysis of Financial Condition
and Results of Operations (MD&A) and other
parts of this Quarterly Report on
Form 10-Q
contain certain forward-looking statements and information
relating to us that are based on the beliefs of our management
as well as assumptions made by, and information currently
available to, us. When used in this document, words such as
anticipate, believe,
estimate, expect, intend,
plan and project and similar
expressions, as they relate to us are intended to identify
forward-looking statements. These statements reflect our current
views with respect to future events, are not guarantees of
future performance and involve risks and uncertainties that are
difficult to predict. Further, certain forward-looking
statements are based upon assumptions as to future events that
may not prove to be accurate. Factors that might cause such
differences include, but are not limited to, those discussed in
the subsection entitled Factors That May Affect Future
Results and Financial Condition below. The following
discussion should be read in conjunction with our 2007
Form 10-K
filed with the Securities and Exchange Commission
(SEC) on February 29, 2008 and the unaudited
interim consolidated financial statements and notes thereto
included elsewhere in this Quarterly Report on
Form 10-Q.
We assume no obligation to revise or update any forward-looking
statements for any reason, except as required by law.
Overview
We are a leading global integrated producer of chemicals and
advanced materials. We are one of the worlds largest
producers of acetyl products, which are intermediate chemicals
for nearly all major industries, as well as a leading global
producer of high-performance engineered polymers that are used
in a variety of high-value end-use applications. As an industry
leader, we hold geographically balanced global positions and
participate in diversified end-use markets. Our operations are
primarily located in North America, Europe and Asia. We combine
a demonstrated track record of execution, strong performance
built on shared principles and objectives, and a clear focus on
growth and value creation.
2008 Highlights:
|
|
|
|
|
Opened a customer application development center in Shanghai,
China, to support growth in the region for Ticonas
engineering polymers business.
|
|
|
|
The Celanese Board of Directors authorized us to repurchase up
to $400 million of its Series A common stock. During
the nine months ended September 30, 2008, we repurchased
9,763,200 shares of its Series A common stock for
$378 million pursuant to this authorization.
|
|
|
|
Upgraded by Moodys Investors Service with a positive
outlook and corporate credit rating of Ba2 from
Ba3.
|
|
|
|
Signed an agreement to establish a 20,000 square-meter
integrated technology and marketing facility in Shanghai. The
facility, expected to be completed in early 2010, will combine
the headquarters for our Asia businesses, customer application
development and research and development center.
|
|
|
|
Successfully started up our newly constructed 20,000 ton
GUR®
ultra-high molecular weight polyethylene
(GUR®)
facility, 100,000 ton acetic anhydride facility and 300,000 ton
vinyl acetate monomer (VAM) facility, all located at
our integrated chemical complex in Nanjing, China.
|
|
|
|
Our Nutrinova business and BRAIN AG, a leading European
white biotech company, identified all-natural
compounds for high intensity sweeteners and sweetness enhancers.
|
30
|
|
|
|
|
Introduced
EcoVAEtm,
a new vinyl acetate/ethylene emulsion technology designed to
facilitate the manufacture of high quality, eco-friendly paints
for North America.
|
|
|
|
Resolved certain legacy litigation matters by entering into a
settlement agreement for $107 million related to sales by
the polyester staple fibers business, which Hoechst AG sold to
KoSa, Inc. in 1998.
|
|
|
|
Announced intent to divest ownership interest in legacy
Infraserv investments located in Knapsack, Gendorf and
Wiesbaden, Germany, where we no longer have manufacturing
operations.
|
|
|
|
Paid 17 million to settle Sorbates antitrust actions
with the European Commission.
|
|
|
|
Announced plans to build a new
Vectra®
liquid crystal polymer (LCP) production facility
co-located at our integrated chemical complex in Nanjing, China.
Construction is scheduled to begin in the first half of 2009,
and the facility is projected to be operational in 2010.
|
|
|
|
Began construction of the worlds largest, state-of-the-art
polyacetal plant in Hoechst Industrial Park. The facility is
expected to be operational in 2011 and will replace
Ticonas existing production operations in Kelsterbach,
Germany.
|
Results
of Operations
Financial
Highlights
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended September 30,
|
|
|
Nine Months Ended September 30,
|
|
|
|
|
|
|
% of
|
|
|
|
|
|
% of
|
|
|
|
|
|
% of
|
|
|
|
|
|
% of
|
|
|
|
2008
|
|
|
Net Sales
|
|
|
2007
|
|
|
Net Sales
|
|
|
2008
|
|
|
Net Sales
|
|
|
2007
|
|
|
Net Sales
|
|
|
|
(unaudited)
|
|
|
|
(in $ millions, except for percentages)
|
|
|
Statement of Operations Data
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net sales
|
|
|
1,823
|
|
|
|
100.0
|
|
|
|
1,573
|
|
|
|
100.0
|
|
|
|
5,537
|
|
|
|
100.0
|
|
|
|
4,684
|
|
|
|
100.0
|
|
Gross profit
|
|
|
333
|
|
|
|
18.3
|
|
|
|
337
|
|
|
|
21.4
|
|
|
|
1,147
|
|
|
|
20.7
|
|
|
|
1,033
|
|
|
|
22.1
|
|
Selling, general and administrative expenses
|
|
|
(142
|
)
|
|
|
(7.8
|
)
|
|
|
(133
|
)
|
|
|
(8.5
|
)
|
|
|
(416
|
)
|
|
|
(7.5
|
)
|
|
|
(371
|
)
|
|
|
(7.9
|
)
|
Other (charges) gains, net
|
|
|
(1
|
)
|
|
|
(0.1
|
)
|
|
|
(12
|
)
|
|
|
(0.8
|
)
|
|
|
(24
|
)
|
|
|
(0.4
|
)
|
|
|
(118
|
)
|
|
|
(2.5
|
)
|
Operating profit
|
|
|
151
|
|
|
|
8.3
|
|
|
|
147
|
|
|
|
9.3
|
|
|
|
592
|
|
|
|
10.7
|
|
|
|
424
|
|
|
|
9.1
|
|
Equity in net earnings of affiliates
|
|
|
19
|
|
|
|
1.0
|
|
|
|
24
|
|
|
|
1.5
|
|
|
|
46
|
|
|
|
0.8
|
|
|
|
65
|
|
|
|
1.4
|
|
Interest expense
|
|
|
(65
|
)
|
|
|
(3.6
|
)
|
|
|
(63
|
)
|
|
|
(4.0
|
)
|
|
|
(195
|
)
|
|
|
(3.5
|
)
|
|
|
(196
|
)
|
|
|
(4.2
|
)
|
Refinancing expense
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(256
|
)
|
|
|
(5.5
|
)
|
Dividend income cost investments
|
|
|
35
|
|
|
|
1.9
|
|
|
|
29
|
|
|
|
1.8
|
|
|
|
138
|
|
|
|
2.5
|
|
|
|
93
|
|
|
|
2.0
|
|
Earnings (loss) from continuing operations before tax and
minority interests
|
|
|
152
|
|
|
|
8.3
|
|
|
|
131
|
|
|
|
8.3
|
|
|
|
617
|
|
|
|
11.1
|
|
|
|
134
|
|
|
|
2.9
|
|
Earnings (loss) from continuing operations
|
|
|
164
|
|
|
|
9.0
|
|
|
|
130
|
|
|
|
8.2
|
|
|
|
512
|
|
|
|
9.3
|
|
|
|
128
|
|
|
|
2.7
|
|
Earnings (loss) from discontinued operations
|
|
|
(6
|
)
|
|
|
(0.3
|
)
|
|
|
(2
|
)
|
|
|
(0.1
|
)
|
|
|
(75
|
)
|
|
|
(1.4
|
)
|
|
|
84
|
|
|
|
1.8
|
|
Net earnings (loss)
|
|
|
158
|
|
|
|
8.7
|
|
|
|
128
|
|
|
|
8.1
|
|
|
|
437
|
|
|
|
7.9
|
|
|
|
212
|
|
|
|
4.5
|
|
Other Data
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Depreciation and amortization
|
|
|
85
|
|
|
|
4.7
|
|
|
|
77
|
|
|
|
4.9
|
|
|
|
250
|
|
|
|
4.5
|
|
|
|
218
|
|
|
|
4.7
|
|
31
|
|
|
|
|
|
|
|
|
|
|
As of
|
|
As of
|
|
|
September 30,
|
|
December 31,
|
|
|
2008
|
|
2007
|
|
|
(unaudited)
|
|
|
(in $ millions)
|
|
Balance Sheet Data
|
|
|
|
|
|
|
|
|
Short-term borrowings and current installments of long-term
debt third party and affiliates
|
|
|
302
|
|
|
|
272
|
|
Add: Long-term debt
|
|
|
3,318
|
|
|
|
3,284
|
|
|
|
|
|
|
|
|
|
|
Total debt
|
|
|
3,620
|
|
|
|
3,556
|
|
|
|
|
|
|
|
|
|
|
Summary
of Consolidated Results for the Three and Nine Months Ended
September 30, 2008 compared to the Three and Nine Months Ended
September 30, 2007
Net sales increased during the three and nine months ended
September 30, 2008 as compared to the same periods in 2007.
An environment of higher raw material and energy costs enabled
price increase initiatives across all segments. Volume increases
were driven by higher acetic acid availability versus the same
periods in 2007, which were affected by the temporary unplanned
outage of the acetic acid unit at our Clear Lake, Texas
facility. These volume increases were offset by the effects of
declining production in the automotive and housing industries
and weakening demand in the United States and Europe during
2008. We expect the economic slowdown in North America and
Europe to continue into the fourth quarter of 2008. We are also
seeing signs of slowing growth in Asia linked to the global
credit crisis. Due to these factors, we anticipate lower overall
sales volumes through the end of 2008. Foreign currency had a
favorable impact on net sales during both the three and nine
month periods ended September 30, 2008 as compared to the
same periods in 2007.
Gross profit as a percentage of net sales and overall gross
profit decreased during the three months ended
September 30, 2008 compared to the same period in 2007 as
the increasing cost of raw materials and energy outpaced overall
price increases. During the nine months ended September 30,
2008, gross profit increased by $114 million, primarily due
to higher prices, strong volumes and favorable foreign currency
effects during the period.
Selling, general and administrative expenses increased
$9 million and $45 million for the three and nine
months ended September 30, 2008, respectively, compared to
the same periods in 2007. Additional spending on business
optimization and finance improvement initiatives increased
selling, general and administrative expenses by $13 million
and $35 million for the three and nine months ended
September 30, 2008, respectively, as compared to the same
periods in 2007.
The components of Other (charges) gains, net are as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended
|
|
Nine Months Ended
|
|
|
September 30,
|
|
September 30,
|
|
|
2008
|
|
2007
|
|
2008
|
|
2007
|
|
|
(unaudited)
|
|
|
(in $ millions)
|
|
Employee termination benefits
|
|
|
(8
|
)
|
|
|
(2
|
)
|
|
|
(19
|
)
|
|
|
(27
|
)
|
Plant/office closures
|
|
|
|
|
|
|
(4
|
)
|
|
|
(7
|
)
|
|
|
(4
|
)
|
Plumbing actions insurance recoveries
|
|
|
|
|
|
|
2
|
|
|
|
|
|
|
|
2
|
|
Ticona Kelsterbach plant relocation
|
|
|
(3
|
)
|
|
|
(1
|
)
|
|
|
(8
|
)
|
|
|
(4
|
)
|
Deferred compensation triggered by Exit Event
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(74
|
)
|
Asset impairments
|
|
|
(21
|
)
|
|
|
(6
|
)
|
|
|
(21
|
)
|
|
|
(9
|
)
|
Clear Lake, Texas insurance recoveries
|
|
|
23
|
|
|
|
|
|
|
|
23
|
|
|
|
|
|
Sorbates antitrust actions
|
|
|
8
|
|
|
|
|
|
|
|
8
|
|
|
|
|
|
Other
|
|
|
|
|
|
|
(1
|
)
|
|
|
|
|
|
|
(2
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total Other (charges) gains, net
|
|
|
(1
|
)
|
|
|
(12
|
)
|
|
|
(24
|
)
|
|
|
(118
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other charges during the three months ended September 30,
2008 primarily includes a $21 million long-lived asset
impairment charge on our Pampa, Texas facility, a
$23 million recovery of insurance claims associated with
the unplanned shutdown of our Clear Lake, Texas facility during
2007 and the release of reserves related to the settlement of
the Sorbates antitrust actions of $8 million, net. See the
accompanying unaudited interim consolidated
32
financial statements for a more thorough description of these
charges and gains. Employee termination benefits costs incurred
during 2008 related to our continued strategy to simplify and
optimize our business portfolio.
During the nine months ended September 30, 2007, other
charges primarily consists of deferred compensation payments. In
May 2007, the Original Shareholders sold their remaining equity
interest in the Company (Exit Event as defined in
the deferred compensation plan document) triggering a clause in
the 2004 deferred compensation program that resulted in the
vesting of certain awards. As a result, the Company expensed
$74 million representing deferred compensation plan
payments for the respective participants 2005 and 2006
contingent benefits.
Operating profit increased $4 million and $168 million
for the three and nine months ended September 30, 2008,
respectively, compared to the same periods in 2007. During the
three month period ended September 30, 2008, lower gross
profit was more than offset by decreased other charges during
2008. During the nine month period ended September 30, 2008
as compared to 2007, increased gross profit and decreased other
charges drove the increase in operating profit.
Equity in net earnings of affiliates decreased $5 million
and $19 million for the three and nine months ended
September 30, 2008, respectively, compared to the same
periods in 2007. The decreases primarily relate to reduced
earnings from our Advanced Engineered Materials affiliates
resulting from higher raw material and energy costs and
decreased demand.
Our effective income tax rate for the three months ended
September 30, 2008 was (8)% compared to 1% for the three
months ended September 30, 2007. The effective income tax
rate decreased for the three months ended September 30,
2008 primarily due to the Companys change in estimate for
the US tax effect on foreign earnings and dividends. Our
effective income tax rate for the nine months ended
September 30, 2008 was 17% compared to 4% for the same
period in 2007. The effective income tax rate increased for the
nine months ended September 30, 2008 primarily due to
income tax benefits recognized in 2007 related to German income
tax reform and US debt refinancing, which were partially offset
by the US income tax effect resulting from the maturity of cross
currency swap arrangements in June 2008 and the lower US tax
effect on foreign earnings and dividends. The overall effective
income tax rate is less than the US statutory federal and state
rates due to income being taxed at lower rates in various
foreign jurisdictions.
Earnings (loss) from discontinued operations for the nine months
ended September 30, 2008 primarily relate to a legal
settlement agreement we entered into in June 2008. Under the
settlement agreement, we agreed to pay $107 million to
resolve certain legacy items. Because the legal proceeding
related to sales by the polyester staple fibers business which
Hoechst AG sold to KoSa, Inc. in 1998, the impact of the
settlement is reflected within discontinued operations in the
current period. See the Polyester Staple Antitrust
Litigation in Note 10 of the accompanying unaudited
interim consolidated financial statements. Earnings (loss) from
discontinued operations during the three months ended
September 30, 2008 consist of legal reserves for current
legal cases related to discontinued operations.
Earnings (loss) from discontinued operations for the three and
nine months ended September 30, 2007 primarily relate to
Acetyl Intermediates sale of its oxo products and
derivatives businesses in February 2007, and the shut down of
our Edmonton, Alberta, Canada methanol facility during the
second quarter of 2007. As a result, revenues and expenses
related to these businesses were reflected as a component of
discontinued operations.
Expansion
in China
The acetic acid facility located in our Nanjing, China complex
achieved normal operations in June 2007 and we commenced
production of vinyl acetate emulsions at the complex during the
fourth quarter of 2007. During the first quarter of 2008, we
commissioned the startup of our
Celstran®
long fiber-reinforced thermoplastic (LFT) unit in
Nanjing. Our newly constructed 20,000 ton
GUR®
facility, 100,000 ton acetic anhydride facility and 300,000 ton
VAM facility started up during the third quarter of 2008.
In 2008, we announced our plans to build both a compounding unit
and an LCP production facility at our Nanjing complex.
Operations for the compounding plant at the complex are expected
to begin by 2009. Construction for the
Vectra®
LCP production facility is scheduled to begin in the first half
of 2009, and the facility is projected to be operational in 2010.
The complex brings world-class scale to one site for the
production of acetic acid, VAM, acetic anhydride, emulsions,
Celstran®
LFT,
GUR®,
an ultra-high molecular weight polyethylene,
Vectra®
liquid crystal polymer and compounding. We believe the Nanjing
complex will further enhance our capabilities to better meet the
growing needs of our customers in a number of industries across
Asia.
33
Selected
Data by Business Segment
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended September 30,
|
|
Nine Months Ended September 30,
|
|
|
|
|
|
|
Change
|
|
|
|
|
|
Change
|
|
|
2008
|
|
2007
|
|
in $
|
|
2008
|
|
2007
|
|
in $
|
|
|
|
|
|
|
(unaudited)
|
|
|
|
|
|
|
|
|
|
|
(in $ millions)
|
|
|
|
|
|
Net sales
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Advanced Engineered Materials
|
|
|
272
|
|
|
|
258
|
|
|
|
14
|
|
|
|
866
|
|
|
|
777
|
|
|
|
89
|
|
Consumer Specialties
|
|
|
295
|
|
|
|
282
|
|
|
|
13
|
|
|
|
869
|
|
|
|
832
|
|
|
|
37
|
|
Industrial Specialties
|
|
|
378
|
|
|
|
314
|
|
|
|
64
|
|
|
|
1,129
|
|
|
|
1,015
|
|
|
|
114
|
|
Acetyl Intermediates
|
|
|
1,056
|
|
|
|
864
|
|
|
|
192
|
|
|
|
3,219
|
|
|
|
2,532
|
|
|
|
687
|
|
Other Activities
|
|
|
|
|
|
|
1
|
|
|
|
(1
|
)
|
|
|
1
|
|
|
|
2
|
|
|
|
(1
|
)
|
Inter-segment eliminations
|
|
|
(178
|
)
|
|
|
(146
|
)
|
|
|
(32
|
)
|
|
|
(547
|
)
|
|
|
(474
|
)
|
|
|
(73
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total net sales
|
|
|
1,823
|
|
|
|
1,573
|
|
|
|
250
|
|
|
|
5,537
|
|
|
|
4,684
|
|
|
|
853
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other (charges) gains, net
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Advanced Engineered Materials
|
|
|
(3
|
)
|
|
|
|
|
|
|
(3
|
)
|
|
|
(9
|
)
|
|
|
(5
|
)
|
|
|
(4
|
)
|
Consumer Specialties
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1
|
)
|
|
|
(8
|
)
|
|
|
7
|
|
Industrial Specialties
|
|
|
|
|
|
|
(7
|
)
|
|
|
7
|
|
|
|
(4
|
)
|
|
|
(26
|
)
|
|
|
22
|
|
Acetyl Intermediates
|
|
|
(5
|
)
|
|
|
(2
|
)
|
|
|
(3
|
)
|
|
|
(14
|
)
|
|
|
(15
|
)
|
|
|
1
|
|
Other Activities
|
|
|
7
|
|
|
|
(3
|
)
|
|
|
10
|
|
|
|
4
|
|
|
|
(64
|
)
|
|
|
68
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total other (charges) gains, net
|
|
|
(1
|
)
|
|
|
(12
|
)
|
|
|
11
|
|
|
|
(24
|
)
|
|
|
(118
|
)
|
|
|
94
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating profit (loss)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Advanced Engineered Materials
|
|
|
13
|
|
|
|
35
|
|
|
|
(22
|
)
|
|
|
80
|
|
|
|
103
|
|
|
|
(23
|
)
|
Consumer Specialties
|
|
|
42
|
|
|
|
34
|
|
|
|
8
|
|
|
|
138
|
|
|
|
130
|
|
|
|
8
|
|
Industrial Specialties
|
|
|
18
|
|
|
|
(9
|
)
|
|
|
27
|
|
|
|
55
|
|
|
|
2
|
|
|
|
53
|
|
Acetyl Intermediates
|
|
|
100
|
|
|
|
117
|
|
|
|
(17
|
)
|
|
|
425
|
|
|
|
340
|
|
|
|
85
|
|
Other Activities
|
|
|
(22
|
)
|
|
|
(30
|
)
|
|
|
8
|
|
|
|
(106
|
)
|
|
|
(151
|
)
|
|
|
45
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total operating profit (loss)
|
|
|
151
|
|
|
|
147
|
|
|
|
4
|
|
|
|
592
|
|
|
|
424
|
|
|
|
168
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Earnings (loss) from continuing operations before tax and
minority interests
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Advanced Engineered Materials
|
|
|
25
|
|
|
|
54
|
|
|
|
(29
|
)
|
|
|
112
|
|
|
|
152
|
|
|
|
(40
|
)
|
Consumer Specialties
|
|
|
43
|
|
|
|
35
|
|
|
|
8
|
|
|
|
187
|
|
|
|
164
|
|
|
|
23
|
|
Industrial Specialties
|
|
|
18
|
|
|
|
(9
|
)
|
|
|
27
|
|
|
|
55
|
|
|
|
2
|
|
|
|
53
|
|
Acetyl Intermediates
|
|
|
133
|
|
|
|
145
|
|
|
|
(12
|
)
|
|
|
520
|
|
|
|
391
|
|
|
|
129
|
|
Other Activities
|
|
|
(67
|
)
|
|
|
(94
|
)
|
|
|
27
|
|
|
|
(257
|
)
|
|
|
(575
|
)
|
|
|
318
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total earnings (loss) from continuing operations before tax and
minority interests
|
|
|
152
|
|
|
|
131
|
|
|
|
21
|
|
|
|
617
|
|
|
|
134
|
|
|
|
483
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Depreciation and amortization
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Advanced Engineered Materials
|
|
|
19
|
|
|
|
17
|
|
|
|
2
|
|
|
|
58
|
|
|
|
51
|
|
|
|
7
|
|
Consumer Specialties
|
|
|
13
|
|
|
|
15
|
|
|
|
(2
|
)
|
|
|
40
|
|
|
|
39
|
|
|
|
1
|
|
Industrial Specialties
|
|
|
15
|
|
|
|
13
|
|
|
|
2
|
|
|
|
43
|
|
|
|
43
|
|
|
|
|
|
Acetyl Intermediates
|
|
|
36
|
|
|
|
31
|
|
|
|
5
|
|
|
|
102
|
|
|
|
81
|
|
|
|
21
|
|
Other Activities
|
|
|
2
|
|
|
|
1
|
|
|
|
1
|
|
|
|
7
|
|
|
|
4
|
|
|
|
3
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total depreciation and amortization
|
|
|
85
|
|
|
|
77
|
|
|
|
8
|
|
|
|
250
|
|
|
|
218
|
|
|
|
32
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
34
Factors
Affecting Segment Net Sales
The charts below set forth the percentage increase (decrease) in
net sales from the 2007 period to the 2008 period attributable
to each of the factors indicated for the following business
segments.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Volume
|
|
|
Price
|
|
|
Currency
|
|
|
Other
|
|
|
Total
|
|
|
|
(unaudited)
|
|
|
|
(in percentages)
|
|
|
Factors Affecting Third Quarter 2008 Segment Net Sales
Compared to Third Quarter 2007
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Advanced Engineered Materials
|
|
|
(6
|
)
|
|
|
6
|
|
|
|
5
|
|
|
|
|
|
|
|
5
|
|
Consumer Specialties
|
|
|
(3
|
)
|
|
|
6
|
|
|
|
2
|
|
|
|
|
|
|
|
5
|
|
Industrial Specialties
|
|
|
1
|
|
|
|
15
|
|
|
|
5
|
|
|
|
(1
|
)(a)
|
|
|
20
|
|
Acetyl Intermediates
|
|
|
9
|
|
|
|
11
|
|
|
|
2
|
|
|
|
|
|
|
|
22
|
|
Total
Company(c)
|
|
|
4
|
|
|
|
11
|
|
|
|
3
|
|
|
|
(2
|
)
|
|
|
16
|
|
Factors Affecting the Nine Months Ended September 30,
2008 Segment Net Sales Compared to the Nine Months Ended
September 30, 2007
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Advanced Engineered Materials
|
|
|
2
|
|
|
|
2
|
|
|
|
7
|
|
|
|
|
|
|
|
11
|
|
Consumer Specialties
|
|
|
(6
|
)
|
|
|
5
|
|
|
|
3
|
|
|
|
2
|
(b)
|
|
|
4
|
|
Industrial Specialties
|
|
|
(7
|
)
|
|
|
13
|
|
|
|
7
|
|
|
|
(2
|
)(a)
|
|
|
11
|
|
Acetyl Intermediates
|
|
|
9
|
|
|
|
14
|
|
|
|
4
|
|
|
|
|
|
|
|
27
|
|
Total
Company(c)
|
|
|
3
|
|
|
|
10
|
|
|
|
6
|
|
|
|
(1
|
)
|
|
|
18
|
|
|
|
|
(a) |
|
Includes the loss of sales related to the AT Plastics
Films business. |
|
(b) |
|
Includes net sales from the Acetate Products Limited
(APL) acquisition. |
|
(c) |
|
Includes the effects of the captive insurance companies. |
Summary
by Business Segment for the Three and Nine Months Ended
September 30, 2008 compared to the Three and Nine Months
Ended September 30, 2007
Advanced
Engineered Materials
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended
|
|
|
Nine Months Ended
|
|
|
|
September 30,
|
|
|
September 30,
|
|
|
|
|
|
|
|
|
|
Change
|
|
|
|
|
|
|
|
|
Change
|
|
|
|
2008
|
|
|
2007
|
|
|
in $
|
|
|
2008
|
|
|
2007
|
|
|
in $
|
|
|
|
(unaudited)
|
|
|
|
(in $ millions, except for percentages)
|
|
|
Net sales
|
|
|
272
|
|
|
|
258
|
|
|
|
14
|
|
|
|
866
|
|
|
|
777
|
|
|
|
89
|
|
Net sales variance:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Volume
|
|
|
(6
|
)%
|
|
|
|
|
|
|
|
|
|
|
2
|
%
|
|
|
|
|
|
|
|
|
Price
|
|
|
6
|
%
|
|
|
|
|
|
|
|
|
|
|
2
|
%
|
|
|
|
|
|
|
|
|
Currency
|
|
|
5
|
%
|
|
|
|
|
|
|
|
|
|
|
7
|
%
|
|
|
|
|
|
|
|
|
Other
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other (charges) gains, net
|
|
|
(3
|
)
|
|
|
|
|
|
|
(3
|
)
|
|
|
(9
|
)
|
|
|
(5
|
)
|
|
|
(4
|
)
|
Operating profit
|
|
|
13
|
|
|
|
35
|
|
|
|
(22
|
)
|
|
|
80
|
|
|
|
103
|
|
|
|
(23
|
)
|
Operating margin
|
|
|
4.8
|
%
|
|
|
13.6
|
%
|
|
|
|
|
|
|
9.2
|
%
|
|
|
13.3
|
%
|
|
|
|
|
Earnings (loss) from continuing operations before tax and
minority interests
|
|
|
25
|
|
|
|
54
|
|
|
|
(29
|
)
|
|
|
112
|
|
|
|
152
|
|
|
|
(40
|
)
|
Depreciation and amortization
|
|
|
19
|
|
|
|
17
|
|
|
|
2
|
|
|
|
58
|
|
|
|
51
|
|
|
|
7
|
|
Our Advanced Engineered Materials segment develops, produces and
supplies a broad portfolio of high-performance technical
polymers for application in automotive and electronics products
and in other consumer and
35
industrial applications, often replacing metal or glass. The
primary products of Advanced Engineered Materials are polyacetal
products (POM), polybutylene terephthalate
(PBT) and
GUR®.
POM and PBT are used in a broad range of products including
automotive components, electronics and appliances.
GUR®
is used in battery separators, conveyor belts, filtration
equipment, coatings and medical devices.
Advanced Engineered Materials net sales increased 5% and
11% for the three and nine months ended September 30, 2008,
respectively, compared to the same periods in 2007. Significant
weakness in the US and European automotive and housing
industries contributed to the decline in sales volumes in the US
and Europe during the three months ended September 30,
2008. Increased volumes in Asia, consisting of both automotive
and nonautomotive applications, partially offset volume declines
in Europe and the US during the three month period ended
September 30, 2008. Net sales benefited from our recent
pricing actions during the three and nine months ended
September 30, 2008. These price increases, however, were
more than offset by higher raw material and energy costs during
the three and nine month periods, contributing to lower
operating profit.
Lower operating profit during the three and nine month periods
was also attributable to higher depreciation and amortization
expense, increased other charges and a $4 million charge
resulting from a non-income tax adjustment. Depreciation and
amortization expenses are higher in 2008 as compared to 2007 due
to the
start-up of
the
GUR®
and LFT units in Asia and foreign currency impacts. Market
indices are not forecasting a rapid
near-term
recovery in demand as it relates to the US and European
automotive and housing industries. Increases to other charges
primarily relate to the relocation of our Ticona plant in
Kelsterbach. See Ticona Kelsterbach Plant Relocation
below.
Our equity affiliates have experienced similar raw material and
energy cost pressures during 2008. As a result, our proportional
share of net earnings of these affiliates during the three and
nine months ended September 30, 2008 was lower than the
same period in 2007.
Ticona
Kelsterbach Plant Relocation
In 2007, we finalized a settlement agreement with the Frankfurt,
Germany, Airport (Fraport) to relocate our
Kelsterbach, Germany, Ticona business resolving several years of
legal disputes related to the planned Frankfurt airport
expansion. As a result of the settlement, we will transition
Ticonas operations from Kelsterbach to the Hoechst
Industrial Park in the Rhine Main area in Germany by mid-2011.
Over a five-year period, Fraport will pay Ticona a total of
670 million to offset the costs associated with the
transition of the business from its current location and the
closure of the Kelsterbach plant. In June 2008, we received
200 million ($311 million) from Fraport under
this agreement. Amounts received from Fraport are accounted for
as deferred proceeds and are included in noncurrent other
liabilities in the accompanying unaudited consolidated balance
sheets as of September 30, 2008 and December 31, 2007.
Additionally, in June 2008, we received 38 million
($59 million) in value-added tax from Fraport of which
38 million ($56 million) was remitted to the tax
authorities in August 2008.
Below is a summary of the financial statement impact associated
with the Ticona Kelsterbach plant relocation:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Nine Months Ended
|
|
|
Total From
|
|
|
|
September 30,
|
|
|
Inception Through
|
|
|
|
2008
|
|
|
2007
|
|
|
September 30, 2008
|
|
|
|
(in $ millions)
|
|
|
Proceeds received from Fraport
|
|
|
311
|
|
|
|
|
|
|
|
337
|
|
Costs expensed
|
|
|
8
|
|
|
|
4
|
|
|
|
13
|
|
Costs capitalized
|
|
|
130
|
(1)
|
|
|
13
|
|
|
|
171
|
|
|
|
|
(1) |
|
Includes increase in accrued capital expenditures of
$8 million. |
36
Consumer
Specialties
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended
|
|
|
Nine Months Ended
|
|
|
|
September 30,
|
|
|
September 30,
|
|
|
|
|
|
|
|
|
|
Change
|
|
|
|
|
|
|
|
|
Change
|
|
|
|
2008
|
|
|
2007
|
|
|
in $
|
|
|
2008
|
|
|
2007
|
|
|
in $
|
|
|
|
(unaudited)
|
|
|
|
(in $ millions, except for percentages)
|
|
|
Net sales
|
|
|
295
|
|
|
|
282
|
|
|
|
13
|
|
|
|
869
|
|
|
|
832
|
|
|
|
37
|
|
Net sales variance:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Volume
|
|
|
(3
|
)%
|
|
|
|
|
|
|
|
|
|
|
(6
|
)%
|
|
|
|
|
|
|
|
|
Price
|
|
|
6
|
%
|
|
|
|
|
|
|
|
|
|
|
5
|
%
|
|
|
|
|
|
|
|
|
Currency
|
|
|
2
|
%
|
|
|
|
|
|
|
|
|
|
|
3
|
%
|
|
|
|
|
|
|
|
|
Other
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2
|
%
|
|
|
|
|
|
|
|
|
Other (charges) gains, net
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1
|
)
|
|
|
(8
|
)
|
|
|
7
|
|
Operating profit
|
|
|
42
|
|
|
|
34
|
|
|
|
8
|
|
|
|
138
|
|
|
|
130
|
|
|
|
8
|
|
Operating margin
|
|
|
14.2
|
%
|
|
|
12.1
|
%
|
|
|
|
|
|
|
15.9
|
%
|
|
|
15.6
|
%
|
|
|
|
|
Earnings (loss) from continuing operations before tax and
minority interests
|
|
|
43
|
|
|
|
35
|
|
|
|
8
|
|
|
|
187
|
|
|
|
164
|
|
|
|
23
|
|
Depreciation and amortization
|
|
|
13
|
|
|
|
15
|
|
|
|
(2
|
)
|
|
|
40
|
|
|
|
39
|
|
|
|
1
|
|
Our Consumer Specialties segment consists of our Acetate
Products and Nutrinova businesses. Our Acetate Products business
primarily produces and supplies acetate tow, which is used in
the production of filter products. We also produce acetate flake
which is processed into acetate fiber in the form of a tow band.
The successful completion of the acquisition of APL on
January 31, 2007 further increased our global position and
enhances our ability to service our customers. Our Nutrinova
business produces and sells
Sunett®,
a high intensity sweetener, and food protection ingredients,
such as sorbates, for the food, beverage and pharmaceuticals
industries.
Higher prices and favorable foreign currency impacts contributed
to increased net sales during the three and nine month periods
ended September 30, 2008 as compared to 2007. Lower sales
volumes during both the three and nine month periods ended
September 30, 2008 are primarily due to our strategic
decision in 2007 to shift flake production to our China
ventures, accounted for using the cost method. As a result, our
flake sales volumes have declined throughout 2008. We expect the
full impact of this decision to be realized by the end of 2008.
Increased tow sales volumes have partially offset decreased
flake volumes and are a direct result of our ability to capture
a portion of the growth in global tow demand. An additional
month of sales from the APL acquisition during the nine months
ended September 30, 2008 as compared to 2007 also
contributed to the increase in net sales.
Higher prices offset rising raw material and energy costs during
the three months ended September 30, 2008, resulting in
higher operating profit. Higher net sales and decreased other
charges drove the increase in operating profit during the nine
months ended September 30, 2008. Other charges during the
nine months ended September 30, 2007 included
$3 million of deferred compensation plan expenses and
$5 million of employee termination benefits.
Earnings (loss) from continuing operations before tax and
minority interests increased consistent with the increase in
operating profit during the three months ended
September 30, 2008. During the nine month period ended
September 30, 2008, the increase in earnings (loss) from
continuing operations before tax and minority interests includes
an increase in dividends from our China ventures of
$11 million as well as increased operating profit.
37
Industrial
Specialties
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended
|
|
|
Nine Months Ended
|
|
|
|
September 30,
|
|
|
September 30,
|
|
|
|
|
|
|
|
|
|
Change
|
|
|
|
|
|
|
|
|
Change
|
|
|
|
2008
|
|
|
2007
|
|
|
in $
|
|
|
2008
|
|
|
2007
|
|
|
in $
|
|
|
|
(unaudited)
|
|
|
|
(in $ millions, except for percentages)
|
|
|
Net sales
|
|
|
378
|
|
|
|
314
|
|
|
|
64
|
|
|
|
1,129
|
|
|
|
1,015
|
|
|
|
114
|
|
Net sales variance:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Volume
|
|
|
1
|
%
|
|
|
|
|
|
|
|
|
|
|
(7
|
)%
|
|
|
|
|
|
|
|
|
Price
|
|
|
15
|
%
|
|
|
|
|
|
|
|
|
|
|
13
|
%
|
|
|
|
|
|
|
|
|
Currency
|
|
|
5
|
%
|
|
|
|
|
|
|
|
|
|
|
7
|
%
|
|
|
|
|
|
|
|
|
Other
|
|
|
(1
|
)%
|
|
|
|
|
|
|
|
|
|
|
(2
|
)%
|
|
|
|
|
|
|
|
|
Other (charges) gains, net
|
|
|
|
|
|
|
(7
|
)
|
|
|
7
|
|
|
|
(4
|
)
|
|
|
(26
|
)
|
|
|
22
|
|
Operating profit
|
|
|
18
|
|
|
|
(9
|
)
|
|
|
27
|
|
|
|
55
|
|
|
|
2
|
|
|
|
53
|
|
Operating margin
|
|
|
4.8
|
%
|
|
|
(2.9
|
)%
|
|
|
|
|
|
|
4.9
|
%
|
|
|
0.2
|
%
|
|
|
|
|
Earnings (loss) from continuing operations before tax and
minority interests
|
|
|
18
|
|
|
|
(9
|
)
|
|
|
27
|
|
|
|
55
|
|
|
|
2
|
|
|
|
53
|
|
Depreciation and amortization
|
|
|
15
|
|
|
|
13
|
|
|
|
2
|
|
|
|
43
|
|
|
|
43
|
|
|
|
|
|
Our Industrial Specialties segment includes our Emulsions,
polyvinyl alcohol (PVOH) and AT Plastics businesses.
Our Emulsions business is a global leader which produces a broad
product portfolio, specializing in vinyl acetate/ethylene
emulsions and is a recognized authority on low VOC (volatile
organic compounds), an environmentally-friendly technology. As a
global leader, our PVOH business produces a broad portfolio of
performance PVOH chemicals engineered to meet specific customer
requirements. Our emulsions and PVOH products are used in a wide
array of applications including paints and coatings, adhesives,
building and construction, glass fiber, textiles and paper. AT
Plastics offers a complete line of low-density polyethylene and
specialty ethylene vinyl acetate copolymers. AT Plastics
products are used in many applications including flexible
packaging films, lamination film products, hot melt adhesives,
medical tubing and automotive carpeting.
Industrial Specialties experienced significant growth in net
sales during the three and nine month periods ended
September 30, 2008 as compared to the same periods in 2007.
Higher pricing was primarily due to continued strong demand for
PVOH and specialty polymers and higher raw material costs.
Volumes remained relatively flat during the three months ended
September 30, 2008 compared to 2007 resulting from the
absence of the third quarter 2007 unplanned outage of our acetic
acid unit at our Clear Lake, Texas facility partially offset by
the interruption of production at Clear Lake during third
quarter 2008 due to Hurricane Ike. Weakened demand in the United
States construction markets and in certain European end-markets
during the nine months ended September 30, 2008, resulted
in lower sales volumes in the Emulsions and PVOH businesses.
However, this has been somewhat offset by Emulsions growth in
sales in Asia and new technology-driven growth programs in North
America.
Operating profit improved as a result of higher net sales and
reduced other charges during the period. During 2007, we
initiated a plan to simplify and optimize our Emulsions and PVOH
businesses to focus on technology and innovation. Other charges
for the nine months ended September 30, 2007 includes a
charge of $15 million for employee termination benefits and
$3 million for impairment of long-lived assets, as a result
of this plan. An additional $4 million for employee
termination benefits were incurred during the nine months ended
September 30, 2008.
38
Acetyl
Intermediates
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended
|
|
|
Nine Months Ended
|
|
|
|
September 30,
|
|
|
September 30,
|
|
|
|
|
|
|
|
|
|
Change
|
|
|
|
|
|
|
|
|
Change
|
|
|
|
2008
|
|
|
2007
|
|
|
in $
|
|
|
2008
|
|
|
2007
|
|
|
in $
|
|
|
|
(unaudited)
|
|
|
|
(in $ millions, except for percentages)
|
|
|
Net sales
|
|
|
1,056
|
|
|
|
864
|
|
|
|
192
|
|
|
|
3,219
|
|
|
|
2,532
|
|
|
|
687
|
|
Net sales variance:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Volume
|
|
|
9
|
%
|
|
|
|
|
|
|
|
|
|
|
9
|
%
|
|
|
|
|
|
|
|
|
Price
|
|
|
11
|
%
|
|
|
|
|
|
|
|
|
|
|
14
|
%
|
|
|
|
|
|
|
|
|
Currency
|
|
|
2
|
%
|
|
|
|
|
|
|
|
|
|
|
4
|
%
|
|
|
|
|
|
|
|
|
Other
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other (charges) gains, net
|
|
|
(5
|
)
|
|
|
(2
|
)
|
|
|
(3
|
)
|
|
|
(14
|
)
|
|
|
(15
|
)
|
|
|
1
|
|
Operating profit
|
|
|
100
|
|
|
|
117
|
|
|
|
(17
|
)
|
|
|
425
|
|
|
|
340
|
|
|
|
85
|
|
Operating margin
|
|
|
9.5
|
%
|
|
|
13.5
|
%
|
|
|
|
|
|
|
13.2
|
%
|
|
|
13.4
|
%
|
|
|
|
|
Earnings (loss) from continuing operations before tax and
minority interests
|
|
|
133
|
|
|
|
145
|
|
|
|
(12
|
)
|
|
|
520
|
|
|
|
391
|
|
|
|
129
|
|
Depreciation and amortization
|
|
|
36
|
|
|
|
31
|
|
|
|
5
|
|
|
|
102
|
|
|
|
81
|
|
|
|
21
|
|
Our Acetyl Intermediates segment produces and supplies acetyl
products, including acetic acid, VAM, acetic anhydride and
acetate esters. These products are generally used as starting
materials for colorants, paints, adhesives, coatings, medicines
and more. Other chemicals produced in this segment are organic
solvents and intermediates for pharmaceutical, agricultural and
chemical products.
Net sales increased substantially during both the three and nine
month periods ended September 30, 2008 as compared to the
same periods in 2007. Volume increases for the three and nine
months ended September 30, 2008 were favorably impacted by
higher acetic acid availability versus the same period in 2007,
which was affected by the temporary unplanned outage of the
acetic acid unit at our Clear Lake, Texas facility. Volume
increases during the nine months ended September 30, 2008
were further impacted by the startup of our acetic acid unit at
our Nanjing, China facility in
mid-2007.
Pricing increases, seen primarily in the Americas and Europe,
were driven in part by formula-based pricing on raw materials,
market tightness in the Americas, and favorable currency impacts
in Europe during the three months ended September 30, 2008.
During the three months ended September 30, 2008, higher
pricing and increased volumes were offset by significant
increases in raw material and energy costs. Hurricane
Ike-related impacts and increased other charges also contributed
to the decline in operating profit during the three month period
ended September 30, 2008. Other charges during the third
quarter 2008 include charges of $7 million in severance and
$21 million in long-lived asset impairment, all of which
are related to the planned shutdown of our Pampa, Texas
facility, offset by $23 million in insurance recoveries
associated with partial satisfaction of loss claims incurred
during the 2007 unplanned shutdown of our Clear Lake, Texas
facility. Operating profit during the nine months ended
September 30, 2008 as compared to 2007 increased 25%
primarily as a result of increased net sales. Fourth quarter
2007 performance was unusually high due to the positive impacts
following global planned and unplanned production outages in the
industry.
Depreciation and amortization expense for the three and nine
months ended September 30, 2008 compared to the same
periods in 2007 increased primarily as a result of the startup
of our acetic acid plant in Nanjing, China in 2007 and as a
result of accelerated depreciation associated with the planned
shutdown of our Pampa, Texas facility.
Earnings (loss) from continuing operations before tax and
minority interests differs from operating profit primarily as a
result of dividend income from our cost investment, Ibn Sina.
Increased dividend income of $8 million and
$34 million for the three and nine months ended
September 30, 2008, respectively, as compared to 2007 had a
positive impact on earnings (loss) from continuing operations
before tax and minority interests. Ibn Sina increased their
dividends as a result of higher earnings from expanding margins
for methanol and methyl tertiary-butyl ether.
39
Other
Activities
Other Activities primarily consists of corporate center costs,
including financing and administrative activities, and our
captive insurance companies.
The operating loss for Other Activities improved $8 million
and $45 million for the three and nine months ended
September 30, 2008, respectively, compared to the same
periods in 2007. The improvement in operating loss was due to
lower other charges partially offset by higher selling, general
and administrative expenses. Other charges decreased principally
due to the release of reserves related to the Sorbates antitrust
actions settlement of $8 million for the three months ended
September 30, 2008 and $59 million in deferred
compensation plan costs that were expensed during the first nine
months of 2007. Selling, general and administrative expenses
increased due to additional spending on business optimization
and finance improvement initiatives of $13 million and
$35 million for the three and nine month periods ended
September 30, 2008, respectively, as compared to the same
periods in 2007.
The loss from continuing operations before tax and minority
interests decreased $27 million and $318 million for
the three and nine months ended September 30, 2008,
respectively, compared to the same periods in 2007. The
significant decrease was primarily due to $256 million of
refinancing expense incurred in conjunction with the 2007 debt
refinancing and the decrease in operating loss discussed above.
Liquidity
and Capital Resources
Our primary source of liquidity is cash generated from
operations, available cash and cash equivalents and dividends
from our portfolio of strategic investments. In addition, we
have $650 million available under our senior credit
facilities to assist, if required, in meeting our working
capital needs and other contractual obligations. In excess of 20
lenders participate in our revolving credit facility, each with
a commitment of less than 10% of the $650 million
commitment. Further, Lehman Brothers Holdings, Inc., which filed
for protection under Chapter 11 of the United States
Bankruptcy Code in September 2008, is not a lender under our
revolving credit facility and we do not have any other material
direct exposure to Lehman Brothers Holdings, Inc. We continue to
believe we will have available resources to meet our liquidity
requirements, including debt service, for the remainder of 2008
and for the subsequent twelve months.
If our cash flow from operations is insufficient to fund our
debt service and other obligations, we may be required to use
other means available to us such as increasing our borrowings,
reducing or delaying capital expenditures, seeking additional
capital or seeking to restructure or refinance our indebtedness.
There can be no assurance, however, that we will continue to
generate cash flows at or above current levels or that we will
be able to maintain our ability to borrow under our revolving
credit facilities.
Cash
Flows
Cash and cash equivalents as of September 30, 2008 were
$584 million, which was a decrease of $241 million
from December 31, 2007.
Net Cash
Provided by Operating Activities
Cash flow from operations increased $66 million during the
nine months ended September 30, 2008 as compared to the
same period in 2007. An increase in operating profit of
$168 million and lower cash taxes paid of $89 million
during the nine months ended September 30, 2008 as compared
to the same period in 2007 contributed to the increase. Also
contributing to the increase was the absence in 2008 of cash
spent on a previous long-term incentive plan, collection of
$30 million in insurance proceeds related to the 2007
shutdown of our acetic acid facility in Clear Lake, Texas (see
Note 18 of the accompanying unaudited interim consolidated
financial statements) and adjustments to cash for discontinued
operations. Adjustments to cash for discontinued operations of
$92 million during the nine months ended September 30,
2007 primarily related to working capital changes of the oxo
products and derivatives businesses we sold and the shutdown of
our Edmonton, Alberta, Canada methanol facility during 2007.
Negative changes to trade working capital and costs incurred in
a legal settlement of $107 million (see the
40
Polyester Staple Antitrust Litigation in
Note 10 of the accompanying unaudited interim consolidated
financial statements) partially offset the increases.
Net Cash
Provided by (Used in) Investing Activities
Net cash from investing activities decreased from a cash inflow
of $196 million for the nine months ended
September 30, 2007 to a cash outflow of $169 million
for the same period in 2008. Cash outflows during the nine
months ended September 30, 2008 included capital
expenditures of $212 million, cash spent on the Ticona
Kelsterbach plant relocation of $122 million and
$93 million spent in settlement of our cross currency swaps
(see Net Investment Hedge below). Cash received from
Fraport in connection with the Ticona Kelsterbach plant
relocation partially offset cash outflows during 2008. Cash
inflows during the nine months ended September 30, 2007
primarily consisted of cash received from the sale of our oxo
products and derivatives businesses, partially offset by cash
outflows spent on the APL acquisition and capital expenditures.
Our cash outflow for capital expenditures were $212 million
and $217 million for the nine months ended
September 30, 2008 and 2007, respectively. Capital
expenditures were primarily related to major replacements of
equipment, capacity expansions, major investments to reduce
future operating costs, and environmental and health and safety
initiatives. Capital expenditures also included cash spent on
the expansion of our integrated chemical complex in Nanjing,
China. Capital expenditures are expected to be approximately
$290 million for 2008.
Net Cash
Used in Financing Activities
Net cash used in financing activities decreased from a cash
outflow of $760 million for the nine months ended
September 30, 2007 to a cash outflow of $402 million
for the same period in 2008. The $358 million decrease
primarily related to cash outflows attributable to the debt
refinancing in 2007 as discussed in Note 6 to the
accompanying unaudited interim consolidated financial
statements. As a result of the refinancing, we incurred a net
cash outflow of $142 million related to repayments of our
debt during the nine months ended September 30, 2007. In
addition, our cash outlay for various refinancing expenses was
$240 million during the nine months ended
September 30, 2007. Cash used to repurchase shares during
the nine months ended September 30, 2008 was
$25 million lower than cash used to repurchase shares
during the same period in 2007.
Liquidity
Our contractual obligations, commitments and debt service
requirements over the next several years are significant. As
stated above, our primary source of liquidity is cash generated
from operations, available cash and cash equivalents and
dividends from our portfolio of strategic investments. In
addition, we have availability under our senior credit agreement
to assist, if required, in meeting our working capital needs and
other contractual obligations.
Celanese has no material assets other than the stock of its
subsidiaries and no independent external operations of its own.
As such, we generally will depend on the cash flow of our
subsidiaries to meet our obligations.
Debt and
Capital
Holders of our preferred stock are entitled to receive, when, as
and if declared by our Board of Directors, out of funds legally
available, cash dividends at the rate of 4.25% per annum (or
$1.06 per share) of liquidation preference, payable quarterly in
arrears commencing on May 1, 2005. Dividends on the
preferred stock are cumulative from the date of initial
issuance. As of September 30, 2008, the dividend is
expected to result in an annual payment of approximately
$10 million. The preferred stock is convertible, at the
option of the holder, at any time into approximately
1.26 shares of our Series A common stock, subject to
adjustments, per $25.00 liquidation preference of the preferred
stock. During the three months ended September 30, 2008 and
2007, we paid $3 million and $2 million, respectively,
of cash dividends on our preferred stock. On October 3,
2008, we declared a $2 million cash dividend on our
preferred stock, which will be paid on November 1, 2008.
In July 2005, our Board of Directors adopted a policy of
declaring, subject to legally available funds, a quarterly cash
dividend on each share of our Series A common stock at an
annual rate initially equal to
41
approximately 1% of the $16.00 initial public offering price per
share of our Series A common stock (or $0.16 per share)
unless our Board of Directors in its sole discretion determines
otherwise. During the three months ended September 30, 2008
and 2007, we paid $6 million of cash dividends in each
period on our Series A common stock and on October 3,
2008, we declared a $6 million cash dividend which will be
paid on November 1, 2008. Based upon the number of
outstanding shares as of September 30, 2008, the annual
cash dividend payment is approximately $24 million.
Our senior credit agreement consists of $2,280 million of
US dollar-denominated and 400 million of
Euro-denominated term loans due 2014, a $650 million
revolving credit facility terminating in 2013 and a
$228 million credit-linked revolving facility terminating
in 2014. Borrowings under the senior credit agreement bear
interest at a variable interest rate based on LIBOR (for US
dollars) or EURIBOR (for Euros), as applicable, or, for US
dollar-denominated loans under certain circumstances, a base
rate, in each case plus an applicable margin. The applicable
margin for the term loans and any loans under the credit-linked
revolving facility is 1.75%, subject to potential reductions as
defined in the senior credit agreement. As of September 30,
2008, the applicable margin was 1.5% and continues to be subject
to potential adjustments as defined in the senior credit
agreement. The term loans under the senior credit agreement are
subject to amortization at 1% of the initial principal amount
per annum, payable quarterly. The remaining principal amount of
the term loans will be due on April 2, 2014.
As of September 30, 2008, we had total debt of
$3,620 million compared to $3,556 million as of
December 31, 2007. We were in compliance with all of the
covenants related to our debt agreements as of
September 30, 2008.
As of September 30, 2008, there were no outstanding
borrowings or letters of credit issued under the revolving
credit facility; accordingly, $650 million remained
available for borrowing. As of September 30, 2008, there
were $92 million of letters of credit issued under the
credit-linked revolving facility and $136 million remained
available for borrowing.
In March 2008, Crystal US Holdings 3 LLC, a subsidiary of
Celanese Corporation, was upgraded by Moodys Investors
Service with a positive outlook and a corporate credit rating of
Ba2 from Ba3.
Contractual Debt and Cash Obligations. There
have been no material revisions to our contractual obligations
as filed in our Annual Report on
Form 10-K
as of and for the year ended December 31, 2007 as filed
with the SEC on February 29, 2008.
Purchases
of Treasury Stock
In February 2008, our Board of Directors authorized the
repurchase of up to $400 million of our Series A
common stock. The authorization gives management discretion in
determining the conditions under which shares may be
repurchased. This repurchase program does not have an expiration
date. During the nine months ended September 30, 2008, we
repurchased 9,763,200 shares of our Series A common
stock at an average purchase price of $38.68 per share for a
total of $378 million pursuant to this authorization.
Treasury stock purchases reduce the number of shares outstanding
and the repurchased shares may be used by us for compensation
programs utilizing our stock and other corporate purposes. We
account for treasury stock using the cost method and include
treasury stock as a component of shareholders equity in
the accompanying unaudited interim consolidated statements of
shareholders equity.
Net
Investment Hedge
To protect the foreign currency exposure of a net investment in
a foreign operation, we entered into cross currency swaps with
certain financial institutions in 2004. Under the terms of the
cross currency swap arrangements, we paid approximately
13 million in interest and received approximately
$16 million in interest on June 15 and December 15 of each
year. Upon maturity of the cross currency swap arrangements in
June 2008, we owed 276 million ($426 million)
and were owed $333 million. In settlement of the
obligation, we paid $93 million (net of interest of
$3 million) in June 2008.
42
In September 2008, we dedesignated 340 million of the
400 million euro-denominated portion of the term
loan, previously designated as a hedge of a net investment of a
foreign operation. Prior to this dedesignation, we entered into
external derivative contracts to offset foreign currency
exposures on intercompany loans. The foreign currency exposure
resulting from dedesignation of 340 million of the
hedge of a net investment of a foreign operation is expected to
offset the foreign currency exposure on certain intercompany
loans, decreasing the need for external derivative contracts and
reducing our exposure to external counterparties. The remaining
60 million euro-denominated portion of the term loan
continues to be designated as a hedge of a net investment of a
foreign operation.
Domination
Agreement
The domination and profit and loss transfer agreement (the
Domination Agreement) was approved at the Celanese
AG (CAG) extraordinary shareholders meeting on
July 31, 2004. The Domination Agreement between CAG and the
Purchaser became effective on October 1, 2004 and cannot be
terminated by the Purchaser in the ordinary course of business
until September 30, 2009. Our subsidiaries, Celanese
International Holdings Luxembourg S.a.r.l. (CIH),
formerly Celanese Caylux Holdings Luxembourg S.C.A., and
Celanese US, have each agreed to provide the Purchaser with
financing to strengthen the Purchasers ability to fulfill
its obligations under, or in connection with, the Domination
Agreement and to ensure that the Purchaser will perform all of
its obligations under, or in connection with, the Domination
Agreement when such obligations become due, including, without
limitation, the obligation to compensate CAG for any statutory
annual loss incurred by CAG during the term of the Domination
Agreement. If CIH
and/or
Celanese US are obligated to make payments under such guarantees
or other security to the Purchaser, we may not have sufficient
funds for payments on our indebtedness when due. We have not had
to compensate CAG for an annual loss for any period during which
the Domination Agreement has been in effect.
Off-Balance
Sheet Arrangements
We have not entered into any material off-balance sheet
arrangements.
Critical
Accounting Policies and Estimates
Our consolidated financial statements are based on the selection
and application of significant accounting policies. The
preparation of consolidated financial statements in conformity
with accounting principles generally accepted in the United
States of America requires management to make estimates and
assumptions that affect the reported amounts of assets and
liabilities, disclosure of contingent assets and liabilities at
the date of the consolidated financial statements and the
reported amounts of revenues, expenses and allocated charges
during the reporting period. Actual results could differ from
those estimates. However, we are not currently aware of any
reasonably likely events or circumstances that would result in
materially different results.
We describe our significant accounting policies in Note 3,
Summary of Accounting Policies, of the Notes to Consolidated
Financial Statements included in our Annual Report on
Form 10-K
as of and for the year ended December 31, 2007. We discuss
our critical accounting policies and estimates in MD&A in
our Annual Report on
Form 10-K
as of and for the year ended December 31, 2007.
There have been no material revisions to the critical accounting
policies as filed in our Annual Report on
Form 10-K
as of and for the year ended December 31, 2007 as filed
with the SEC on February 29, 2008.
On January 1, 2008, we adopted the provisions of Statement
of Financial Accounting Standard No. 157, Fair Value
Measurements (SFAS No. 157) for
financial assets and liabilities. SFAS No. 157 defines
fair value, thereby eliminating inconsistencies in guidance
found in various prior accounting pronouncements, and increases
disclosures surrounding fair value calculations. The adoption of
SFAS No. 157 for financial assets and liabilities did
not have a material impact on our statement of operations,
financial position or cash flows for the nine months ended
September 30, 2008.
43
SFAS No. 157 establishes a three-tiered fair value
hierarchy that prioritizes inputs to valuation techniques used
in fair value calculations. The three levels of inputs are
defined as follows:
Level 1 unadjusted quoted prices for identical
assets or liabilities in active markets accessible by us
Level 2 inputs that are observable in the
marketplace other than those inputs classified as Level 1
Level 3 inputs that are unobservable in the
marketplace and significant to the valuation
SFAS No. 157 requires us to maximize the use of
observable inputs and minimize the use of unobservable inputs.
If a financial instrument uses inputs that fall in different
levels of the hierarchy, the instrument will be categorized
based upon the lowest level of input that is significant to the
fair value calculation.
Our financial assets and liabilities are measured at fair value
on a recurring basis and include securities available for sale
and derivative financial instruments. Securities available for
sale include US government and corporate bonds, mortgage-backed
securities and equity securities. Derivative financial
instruments include interest rate swaps and foreign currency
forwards and swaps.
Marketable Securities. Where possible, we
utilize quoted prices in active markets to measure debt and
equity securities; such items are classified as Level 1 in
the hierarchy and include equity securities and US government
bonds. When quoted market prices for identical assets are
unavailable, varying valuation techniques are used. Common
inputs in valuing these assets include, among others, benchmark
yields, issuer spreads, forward mortgage-backed securities trade
prices and recently reported trades. Such assets are classified
as Level 2 in the hierarchy and typically include
mortgage-backed securities, corporate bonds and other US
government securities.
Derivatives. Derivative financial instruments
are valued in the market using discounted cash flow techniques.
These techniques incorporate Level 1 and Level 2
inputs such as interest rates and foreign currency exchange
rates. These market inputs are utilized in the discounted cash
flow calculation considering the instruments term,
notional amount, discount rate and credit risk. Significant
inputs to the derivative valuation for interest rate swaps and
foreign currency forwards and swaps are observable in the active
markets and are classified as Level 2 in the hierarchy.
Recent
Accounting Pronouncements
See Notes 2 and 11 of the accompanying unaudited interim
consolidated financial statements included in this
Form 10-Q
for a discussion of recent accounting pronouncements.
Factors
That May Affect Future Results and Financial Condition
Because of the following factors, as well as other factors
affecting our operating results and financial condition, past
financial performance should not be considered to be a reliable
indicator of future performance, and investors should not use
historical trends to anticipate results or trends in future
periods. In addition, many factors could cause our actual
results, performance or achievements to be materially different
from any future results, performance or achievements that may be
expressed or implied by such forward-looking statements. These
factors include, among other things:
|
|
|
|
|
changes in general economic, business, political and regulatory
conditions in the countries or regions in which we operate;
|
|
|
|
the length and depth of product and industry business cycles
particularly in the automotive, electrical, electronics and
construction industries;
|
|
|
|
changes in the price and availability of raw materials,
particularly changes in the demand for, supply of, and market
prices of fuel oil, methanol, natural gas, coal, electricity and
petrochemicals such as ethylene and butane;
|
|
|
|
the ability to pass increases in raw material prices on to
customers or otherwise improve margins through price increases;
|
|
|
|
the ability to maintain plant utilization rates and to implement
planned capacity additions and expansions;
|
44
|
|
|
|
|
the ability to reduce production costs and improve productivity
by implementing technological improvements to existing plants;
|
|
|
|
increased price competition and the introduction of competing
products by other companies;
|
|
|
|
changes in the degree of intellectual property and other legal
protection afforded to our products;
|
|
|
|
compliance costs and potential disruption or interruption of
production due to accidents or other unforeseen events or delays
in construction of facilities;
|
|
|
|
potential liability for remedial actions under existing or
future environmental regulations;
|
|
|
|
potential liability resulting from pending or future litigation,
or from changes in the laws, regulations or policies of
governments or other governmental activities in the countries in
which we operate;
|
|
|
|
changes in currency exchange rates and interest rates; and
|
|
|
|
various other factors, both referenced and not referenced in
this document.
|
Many of these factors are macroeconomic in nature and are,
therefore, beyond our control. Additional information concerning
these and other factors can be found in our Annual Report on
Form 10-K
filed with the SEC on February 29, 2008, including in
Item 1A Risk Factors, and as may be
updated in Part II, Item 1A Risk
Factors, of this interim report on
Form 10-Q.
Should one or more of these risks or uncertainties materialize,
or should underlying assumptions prove incorrect, our actual
results, performance or achievements may vary materially from
those described in this Quarterly Report as anticipated,
believed, estimated, expected, intended, planned or projected.
We neither intend nor assume any obligation to update these
forward-looking statements, which speak only as of their dates.
|
|
Item 3.
|
Quantitative
and Qualitative Disclosures about Market Risk
|
Market risk for our Company has not changed materially from the
foreign exchange, interest rate and commodity risks disclosed in
Item 7A in our Annual Report on
Form 10-K
as of and for the year ended December 31, 2007 as filed
with the SEC on February 29, 2008. However, market risk
associated with the foreign currency exposure of a net
investment in a foreign operation has changed due to the
settlement of the cross currency swap arrangements. To protect
the foreign currency exposure of a net investment in a foreign
operation, we entered into cross currency swaps with certain
financial institutions in 2004. Under the terms of the cross
currency swap arrangements, we paid approximately
13 million in interest and received approximately
$16 million in interest on June 15 and December 15 of each
year. The fair value of the net obligation under the cross
currency swaps was included in current other liabilities in the
accompanying unaudited consolidated balance sheet at
December 31, 2007. Upon maturity of the cross currency swap
arrangements in June 2008, we owed 276 million
($426 million) and were owed $333 million. In
settlement of the obligation, we paid $93 million (net of
interest of $3 million) in June 2008.
In September 2008, we dedesignated 340 million of the
400 million euro-denominated portion of the term
loan, previously designated as a hedge of a net investment of a
foreign operation. Prior to this dedesignation, we entered into
external derivative contracts to offset foreign currency
exposures on intercompany loans. The foreign currency exposure
resulting from dedesignation of 340 million of the
hedge of a net investment of a foreign operation is expected to
offset the foreign currency exposure on certain intercompany
loans, decreasing the need for external derivative contracts and
reducing our exposure to external counterparties. The remaining
60 million euro-denominated portion of the term loan
continues to be designated as a hedge of a net investment of a
foreign operation.
This net investment along with a portion of other assets,
liabilities, revenues and expenses are denominated in currencies
other than the US dollar, principally the Euro. Fluctuations in
the value of these currencies against the US dollar,
particularly the value of the Euro, can have a direct and
material impact on our business and financial results.
45
|
|
Item 4.
|
Controls
and Procedures
|
Under the supervision and with the participation of our
management, including the Chief Executive Officer and Chief
Financial Officer, we have evaluated the effectiveness of our
disclosure controls and procedures pursuant to Exchange Act
Rule 13a-15(b)
as of the end of the period covered by this report. Based on
that evaluation, the Chief Executive Officer and Chief Financial
Officer have concluded that these disclosure controls and
procedures are effective.
Changes
in Internal Control Over Financial Reporting
We are currently transitioning finance and accounting functions
from multiple locations in various countries to a Financial
Shared Service Center in Budapest, Hungary. This transformation
has involved significant changes in personnel and certain
changes to internal processes and control procedures; however,
the basic internal controls over financial reporting have not
materially changed. As of the end of the period covered by this
report, there were no changes in internal control over financial
reporting that have materially affected, or are reasonably
likely to materially affect, our internal control over financial
reporting.
PART II
OTHER INFORMATION
|
|
Item 1.
|
Legal
Proceedings
|
We are involved in a number of legal proceedings, lawsuits and
claims incidental to the normal conduct of our business,
relating to such matters as product liability, antitrust, past
waste disposal practices and release of chemicals into the
environment. While it is impossible at this time to determine
with certainty the ultimate outcome of these proceedings,
lawsuits and claims, we believe, based on the advice of legal
counsel, that adequate provisions have been made and that the
ultimate outcomes will not have a material adverse effect on our
financial position, but may have a material adverse effect on
our results of operations or cash flows in any given accounting
period. See also Note 10 to the unaudited interim
consolidated financial statements for a discussion of legal
proceedings.
There have been no significant developments in the Legal
Proceedings described in our Annual Report on
Form 10-K
as of and for the year ended December 31, 2007 as filed
with the SEC on February 29, 2008 other than those
disclosed in Note 10 to the unaudited interim consolidated
financial statements.
There have been no material revisions to the Risk
factors as filed in our Annual Report on
Form 10-K
as of and for the year ended December 31, 2007 (2007
Form 10-K)
with the SEC on February 29, 2008 other than the revised
risk factor below, which replaces the risk factor appearing in
our 2007
Form 10-K
entitled Changes in environmental, health, and safety
regulatory requirements could lead to a decrease in demand for
our products.
Changes
in environmental, health and safety regulations in the
jurisdictions where we manufacture and sell our products could
lead to a decrease in demand for our products.
New or revised governmental regulations and independent studies
relating to the effect of our products on health, safety and the
environment may affect demand for our products and the cost of
producing our products.
Canada recently included vinyl acetate monomer (VAM)
as one of approximately 200 chemicals being assessed as part of
the Canadian Governments Chemicals Management Plan under
the Canadian Environmental Protection Act (CEPA). On
May 16, 2008, Health Canada published a draft screening
risk assessment and draft risk management scope document for VAM
that concluded, using a precautionary approach, that
VAM be listed as a toxic substance under CEPA. If
this classification is finalized, Health Canada will proceed to
develop a risk management plan that could impose conditions and
restrictions on the use of VAM in Canada, including the
prohibition of VAM in some end uses and the limitation of
residual VAM in others. The Company and other manufacturers and
users of VAM have provided Health Canada with information on
toxicological properties of VAM and the residual levels of VAM
in products manufactured or distributed in Canada.
Notwithstanding, it is unclear at this point which VAM
classification Health Canada will adopt. If Canada adopts its
current proposal, this
46
may encourage other jurisdictions to adopt similar standards
which could have an adverse impact on our business and results
of operations.
The Registration, Evaluation, Authorization and Restriction of
Chemicals (REACh), which established a system to
register and evaluate chemicals manufactured in, or imported to,
the European Union, became effective on June 1, 2007. VAM
is one of the chemicals that the European Chemicals Agency
(ECHA) will regulate under REACh. ECHA will likely
rely on the work of the EU-Working group on classification and
labeling of dangerous substances. After extensive study, the
EU-Working Group agreed that VAM should be classified in the EU
as showing limited evidence of a carcinogenic effect. In
addition, a risk assessment was performed on VAM by the European
Chemicals Bureau of the European Commission. Risk reduction
strategies for human health and the environment were finalized
without the imposition of any restrictions or burdens atypical
to an industrial chemical. We can provide no assurance that the
EU classifications on VAM will not be revised in the future, or
that other chemicals we produce will not be classified in a
manner that would adversely affect demand for such products.
Such negative classifications could have an adverse affect on
our business and results of operations.
We are a producer of formaldehyde and plastics derived from
formaldehyde. Several studies have investigated possible links
between formaldehyde exposure and various end points including
leukemia. The International Agency for Research on Cancer
(IARC), a private research agency, has reclassified
formaldehyde from Group 2A (probable human carcinogen) to Group
1 (known human carcinogen) based on studies linking formaldehyde
exposure to nasopharyngeal cancer, a rare cancer in humans. We
expect the results of IARCs review will be examined and
considered by government agencies with responsibility for
setting worker and environmental exposure standards and labeling
requirements. If such agencies give strong consideration to
IARCs findings in setting such standards and requirements,
it could have an adverse effect on our business.
Other pending initiatives will potentially require toxicological
testing and risk assessments of a wide variety of chemicals,
including chemicals used or produced by us. These initiatives
include the Voluntary Childrens Chemical Evaluation
Program and High Production Volume Chemical Initiative in the
United States, as well as various European Commission programs,
such as REACh and the European Environment and Health Strategy
(SCALE).
The above-mentioned assessments in the United States, Canada and
Europe may result in heightened concerns about the chemicals
involved and additional requirements being placed on the
production, handling, labeling or use of the subject chemicals.
Such concerns and additional requirements could increase the
cost incurred by our customers to use our chemical products and
otherwise limit the use of these products, which could lead to a
decrease in demand for these products. Such a decrease in demand
would likely have an adverse impact on our business and results
of operations.
|
|
Item 2.
|
Unregistered
Sales of Equity Securities and Use of Proceeds
|
The table below sets forth information regarding repurchases of
our Series A common stock during the three months ended
September 30, 2008:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Approximate Dollar
|
|
|
|
|
|
|
|
|
|
Total Number of
|
|
|
Value of Shares
|
|
|
|
Total Number
|
|
|
Average
|
|
|
Shares Purchased as
|
|
|
Remaining that may be
|
|
|
|
of Shares
|
|
|
Price Paid
|
|
|
Part of Publicly
|
|
|
Purchased Under
|
|
Period
|
|
Purchased(1)
|
|
|
per Share
|
|
|
Announced Program
|
|
|
the Program
|
|
|
July 24-31,
2008
|
|
|
1,630,000
|
|
|
$
|
39.11
|
|
|
|
1,630,000
|
|
|
$
|
210,400,000
|
|
August 1-29, 2008
|
|
|
2,950,000
|
|
|
$
|
37.59
|
|
|
|
2,950,000
|
|
|
$
|
99,500,000
|
|
September 2-17, 2008
|
|
|
2,234,300
|
|
|
$
|
34.52
|
|
|
|
2,234,300
|
|
|
$
|
22,300,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
|
6,814,300
|
|
|
|
|
|
|
|
6,814,300
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1) |
|
Purchased pursuant to the $400 million share repurchase
program publicly announced on February 11, 2008. This
repurchase program does not have an expiration date. |
47
|
|
Item 3.
|
Defaults
Upon Senior Securities
|
None.
|
|
Item 4.
|
Submission
of Matters to a Vote of Security Holders
|
None.
|
|
Item 5.
|
Other
Information
|
None.
|
|
|
|
|
Exhibit
|
|
|
Number
|
|
Description
|
|
|
3
|
.1
|
|
Second Amended and Restated Certificate of Incorporation
(incorporated by reference to Exhibit 3.1 to the Current
Report on
Form 8-K
filed with the SEC on January 28, 2005).
|
|
3
|
.2
|
|
Second Amended and Restated By-laws, effective as of
February 8, 2008 (incorporated by reference to
Exhibit 3.2 to the Current Report on
Form 8-K
filed with the SEC on February 14, 2008).
|
|
3
|
.3
|
|
Certificate of Designations of 4.25% Convertible Perpetual
Preferred Stock (incorporated by reference to Exhibit 3.2
to the Current Report on
Form 8-K
filed with the SEC on January 28, 2005).
|
|
10
|
.1
|
|
Change in Control Agreement, dated June 5, 2008 between the
Company and Michael L. Summers (filed herewith).
|
|
10
|
.2
|
|
Agreement and General Release, dated September 25, 2008
between the Company and Curtis S. Shaw (filed herewith).
|
|
10
|
.3
|
|
Sign-on Restricted Stock Unit Award Agreement, dated
July 23, 2008 between the Company and Michael L. Summers
(filed herewith).
|
|
10
|
.4
|
|
Agreement and General Release, dated March 28, 2008 between the
Company and William P. Antonace (filed herewith).
|
|
10
|
.5
|
|
Nonqualified Stock Option Award Agreement, dated April 23,
2008 between the Company and Christopher Jensen (filed
herewith).
|
|
10
|
.6
|
|
Time-Vesting Restricted Stock Unit Award Agreement, dated
April 23, 2008 between the Company and Christopher Jensen
(filed herewith).
|
|
31
|
.1
|
|
Certification of Chief Executive Officer pursuant to
Section 302 of the Sarbanes-Oxley Act of 2002 (filed
herewith).
|
|
31
|
.2
|
|
Certification of Chief Financial Officer pursuant to
Section 302 of the Sarbanes-Oxley Act of 2002 (filed
herewith).
|
|
32
|
.1
|
|
Certification of Chief Executive Officer pursuant to
Section 906 of the Sarbanes-Oxley Act of 2002 (filed
herewith).
|
|
32
|
.2
|
|
Certification of Chief Financial Officer pursuant to
Section 906 of the Sarbanes-Oxley Act of 2002 (filed
herewith).
|
PLEASE NOTE: It is inappropriate for readers
to assume the accuracy of, or rely upon any covenants,
representations or warranties that may be contained in
agreements or other documents filed as Exhibits to, or
incorporated by reference in, this Quarterly Report. Any such
covenants, representations or warranties may have been qualified
or superseded by disclosures contained in separate schedules or
exhibits not filed with or incorporated by reference in this
Quarterly Report, may reflect the parties negotiated risk
allocation in the particular transaction, may be qualified by
materiality standards that differ from those applicable for
securities law purposes, and may not be true as of the date of
this Quarterly Report or any other date and may be subject to
waivers by any or all of the parties. Where exhibits and
schedules to agreements filed or incorporated by reference as
Exhibits hereto are not included in these exhibits, such
exhibits and schedules to agreements are not included or
incorporated by reference herein.
48
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned thereunto duly authorized.
CELANESE CORPORATION
Name: David N. Weidman
|
|
|
|
Title:
|
Chairman of the Board of Directors and Chief Executive Officer
|
Date: October 22, 2008
Name: Steven M. Sterin
|
|
|
|
Title:
|
Senior Vice President and
Chief Financial Officer
|
Date: October 22, 2008
49